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A B S T R A C T
Background
The role of vitamin C (ascorbic acid) in the prevention and treatment of the common cold has been a subject of controversy for 60
years, but is widely sold and used as both a preventive and therapeutic agent.
Objectives
To discover whether oral doses of 0.2 g or more daily of vitamin C reduces the incidence, duration or severity of the common cold
when used either as continuous prophylaxis or after the onset of symptoms.
Search strategy
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 4, 2006); MEDLINE (1966
to December 2006); and EMBASE (1990 to December 2006).
Selection criteria
Papers were excluded if a dose less than 0.2 g per day of vitamin C was used, or if there was no placebo comparison.
Data collection and analysis
Two review authors independently extracted data and assessed trial quality. ’Incidence’ of colds during prophylaxis was assessed as the
proportion of participants experiencing one or more colds during the study period. ’Duration’ was the mean days of illness of cold
episodes.
Main results
Thirty trial comparisons involving 11,350 study participants contributed to the meta-analysis on the relative risk (RR) of developing
a cold whilst taking prophylactic vitamin C. The pooled RR was 0.96 (95% confidence intervals (CI) 0.92 to 1.00). A subgroup of
six trials involving a total of 642 marathon runners, skiers, and soldiers on sub-arctic exercises reported a pooled RR of 0.50 (95% CI
0.38 to 0.66).
Thirty comparisons involving 9676 respiratory episodes contributed to a meta-analysis on common cold duration during prophylaxis.
A consistent benefit was observed, representing a reduction in cold duration of 8% (95% CI 3% to 13%) for adults and 13.6% (95%
CI 5% to 22%) for children.
Seven trial comparisons involving 3294 respiratory episodes contributed to the meta-analysis of cold duration during therapy with
vitamin C initiated after the onset of symptoms. No significant differences from placebo were seen. Four trial comparisons involving
2753 respiratory episodes contributed to the meta-analysis of cold severity during therapy and no significant differences from placebo
were seen.
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Authors’ conclusions
The failure of vitamin C supplementation to reduce the incidence of colds in the normal population indicates that routine mega-dose
prophylaxis is not rationally justified for community use. But evidence suggests that it could be justified in people exposed to brief
periods of severe physical exercise or cold environments.
P L A I N L A N G U A G E S U M M A R Y
Vitamin C for preventing and treating the common cold
The term ’the common cold’ does not denote a precisely defined disease, yet the characteristics of this illness are familiar to most people.
It is a major cause of visits to a doctor in Western countries and of absenteeism from work and school. It is usually caused by respiratory
viruses for which antibiotics are useless. Other potential treatment options are of substantial public health interest.
Since vitamin C was isolated in the 1930s it has been proposed for respiratory infections, and became particularly popular in the 1970s
for the common cold when (Nobel Prize winner) Linus Pauling drew conclusions from earlier placebo-controlled trials of large dose
vitamin C on the incidence of colds. New trials were undertaken.
This review is restricted to placebo-controlled trials testing at least 0.2 g per day of vitamin C. Thirty trials involving 11,350 participants
suggest that regular ingestion of vitamin C has no effect on common cold incidence in the ordinary population. It reduced the duration
and severity of common cold symptoms slightly, although the magnitude of the effect was so small its clinical usefulness is doubtful.
Nevertheless, in six trials with participants exposed to short periods of extreme physical or cold stress or both (including marathon
runners and skiers) vitamin C reduced the common cold risk by half.
Trials of high doses of vitamin C administered therapeutically (starting after the onset of symptoms), showed no consistent effect on
either duration or severity of symptoms. However, there were only a few therapeutic trials and their quality was variable. One large
trial reported equivocal benefit from an 8 g therapeutic dose at the onset of symptoms, and two trials using five-day supplementation
reported benefit. More therapeutic trials are necessary to settle the question, especially in children who have not entered these trials.
B A C K G R O U N D
Numerous animal studies with different species have shown that
vitamin C affects resistance to diverse infections by viruses and
bacteria (Hemilä 2006a; Hemilä 1997c). It might therefore be
expected that this vitamin would also play such a role in human
beings, but its importance in this regard is unresolved. Since the
early 1940s, a large number of controlled trials have been carried
out to examine the possible effects of vitamin C on the common
cold, a ubiquitous problem caused by a wide range of viral agents.
The common cold causes enormous morbidity worldwide and the
search for simple and effective preventive or therapeutic agents or
both has been elusive.
In 1970, the publication of Pauling 1970a, a book for the general
public entitled “Vitamin C and the Common Cold” generated
huge public interest which persists today. Linus Pauling was a
double Nobel Laureate in chemistry and peace. Pauling 1971a also
carried out a meta-analysis in which he combined the P values
derived from four placebo-controlled trials by Fisher’s method and
found that there was strong evidence that vitamin C decreases the
’incidence of colds’ (P = 0.003). In a secondmeta-analysis, Pauling
1971b focused on ’days of illness per person’ in the best two of the
four trials (Cowan 1942; Ritzel 1961) and combining the P values
by Fisher’s method, led him to conclude that “the null hypothesis
of equal effectiveness of ascorbic acid and placebo is rejected at the
level P less than 0.001.”
Ritzel 1961 had reported a brief randomised controlled trial of
children at a ski school in the Swiss Alps in which he administered
1 g daily and found reduced incidence and duration of colds in the
recipients of vitamin C. Pauling put much weight on the Ritzel
trial and based his expectations of vitamin C benefits on it. Pauling
1970b and Pauling 1976 also presented other data suggesting that
human diets might not provide sufficient intake of vitamin C for
optimal health, and proposed that mega-dose supplementation
might profoundly influence both the incidence and severity of the
common cold.
Pauling’s advocacy of vitamin C led to numerous careful trials in
different countries in the following decade, the largest of which
were performed on healthy adult volunteers in Canada (Anderson
1972; Anderson 1974a; Anderson 1975a).
The evidence emerging from these trials was often confusing (An-
derson 1977), but generally failed to support Pauling’s hope that
vitamin C would be a panacea. Chalmers 1975 calculated an un-
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weighted average of the treatment effect in seven placebo-con-
trolled trials and found that colds in vitamin C groups were 0.11 ±
0.24 (standard error (SE)) days shorter, and the incidence of colds
in vitamin C groups was 0.09 ± 0.06 (SE) episodes less per year,
neither of which is a statistically or clinically significant difference.
In a qualitative review on vitamin C and the common cold pub-
lished in the same year, Dykes 1975 also concluded that vitamin
C had no effect on colds.
However, it has subsequently been claimed that the influential re-
views by Chalmers 1975 and Dykes 1975 contain errors (Hemilä
1995; Hemilä 1996c; see p. 36-45 in Hemilä 2006a). Further-
more, both Chalmers 1975 and Dykes 1975 placed considerable
weight on the double-blind placebo-controlled trial carried out
by Karlowski 1975a at the National Institutes of Health (NIH),
which concluded that a statistically significant benefit of vitamin
C supplementation was simply caused by the placebo effect. It
has subsequently been argued that the placebo-explanation in the
Karlowski paper (Karlowski 1975a; Karlowski 1975b; Karlowski
1975c) was not consistent with their own data (Chalmers 1996;
Hemilä 1996a; Hemilä 1996d; see p. 21-5 in Hemilä 2006a).
Hemilä (Hemilä 1997b; Hemilä 2006a) claimed that the highly
cited reviews of Chalmers 1975 and Dykes 1975 and the trial by
Karlowski 1975a quelled interest in the real, but modest effects of
vitamin C on the common cold after the mid-seventies. Hemilä
1997a pooled the results of the six largest trials and found no effect
on common cold incidence using 1 g/day or more of vitamin C
(pooled relative risk (RR) 0.99; 95% CI 0.93 to 1.04). However,
four trials with UK males found moderate reduction in common
cold incidence with vitamin C (pooled RR 0.70; 0.60 to 0.81).
This was suggested to have been caused by the particularly low
dietary vitamin C intake in the UK rather than high doses of sup-
plements. Also, three trials with participants under heavy acute
physical stress had reported reduced incidence of colds with vita-
min C (pooled RR 0.50; 0.35 to 0.69) (Hemilä 1996b).
Although regular vitamin C supplementation at doses of 1 g/day
or more has consistently decreased the duration or alleviated the
symptoms of the common cold, there was substantial heterogene-
ity in the results (Hemilä 1994). A further meta-analysis found
a trend for trials with children to show greater benefit than trials
with adults, and another trend for trials with 2 g/day or more to
show greater benefit than trials with 1 g/day indicating dose-de-
pendency (Hemilä 1999a).
In the first edition of this Cochrane review (Douglas 1998a), an
analysis was made of the 30 published trials that had been selected
for attention by two previous systematic reviewers, Hemilä 1992
and Kleijnen 1989. That selection of trials was one of convenience
and was justified by the fact that all had been carried out post-
Pauling in an era of relatively sophisticated trial methodology, and
mainly using doses of vitamin C at the level recommended by
Pauling.
For the 2004 revised edition of this Cochrane review, all known
publications on the topic in the past 64 years were included. Some
of these trials had been carried out since the original 1998 review.
Twenty-five additional trials were added to the review, including
a number of trials which evaluated the utility of vitamin C in
the prevention of post-race colds among marathon runners and
further explored the role of vitamin C as a therapy for colds. In
this 2007 update, one new trial was identified (Sasazuki 2006).
The terms ’common cold’ and ’coryza’ are used loosely both gener-
ally and in these trials. Most investigators have used self report by
participants of a widely agreed constellation of symptoms and the
self-assessed duration and severity of those symptoms, to evaluate
the impact of vitamin C supplementation.
Three distinct evaluative approaches are discernible in the trials
which have been conducted.
(1) Laboratory trials in which volunteers were artificially exposed,
in a laboratory setting, to known respiratory viruses, after prelim-
inary dosage with vitamin C or placebo.
(2) Community prophylaxis trials in which volunteers took reg-
ular daily supplements of vitamin C or placebo over a study pe-
riod ranging from weeks to months, in an effort to prevent the
acquisition of colds and to ameliorate the effects of the colds that
occurred. In some of these trials, medication was increased during
the first few days of the colds that occurred.
(3) Community therapeutic trials which evaluated the therapeu-
tic effects of vitamin C that was commenced only after naturally
acquired cold symptoms had developed.
Links to the publications cited in this section, for which full text
versions are available, can be found at www.ltdk.helsinki.fi/users/
hemila/CC/.
O B J E C T I V E S
The central question for the review is: does vitamin C in doses of
0.2 g daily or more, reduce the incidence, duration or severity of
the common cold when used either as continuous prophylaxis or
at the onset of cold symptoms.
C R I T E R I A F O R C O N S I D E R I N G
S T U D I E S F O R T H I S R E V I E W
Types of studies
Included studies were placebo-controlled trials of vitamin C to
prevent or treat the common cold using oral doses of vitamin C
of 0.2 g/day or more, and comparing outcomes with a placebo
preparation. The description of the study must enable it to be
methodologically assessed using the Jadad quality score (Jadad
1996) and provide statistical data that could be entered into one
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or more of the five meta-analyses. These were the minimal criteria
for inclusion of a trial in the review.
Types of participants
Trials of children and adults of either gender and any age were
considered eligible.
Types of intervention
The only interventions considered were comparisons of orally ad-
ministered vitamin C of at least 0.2 g daily and a placebo. In a
few instances the placebo included a low dose of vitamin C; Carr
1981a used 70 mg/day, whereas a few others used 50 mg/day or
less. This has been done by some investigators to ensure that par-
ticipants were not vitamin C ’deficient’, recognising that regular
dietary intake of vitamin C is highly variable in some groups.
Types of outcome measures
’Incidence’ of colds during prophylaxis was assessed as the pro-
portion of participants experiencing one or more colds during the
study period.
’Duration’ was themean number of days of illness of cold episodes.
’Severity’ of these episodes was assessed in two ways: days confined
indoors, or off work or off school per episode and by symptom
severity scores.
’Evidence of possible medication side effects’ was available from
seven large prophylaxis studies, with the number of participants
reporting possible medication side effects in the active and control
groups.
S E A R C H M E T H O D S F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: Cochrane Acute Respiratory Infections Group methods used
in reviews.
For the 2004 update, we searched the following electronic
databases: the Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library Issue 2, 2004); MEDLINE
(January 1966 to June 2004); and EMBASE (1990 to June Week
23 2004). We ran the following search strings in combination
with the search strategy developed by the Cochrane Collaboration
for identifying randomised controlled trials (Dickersin 1994).
MEDLINE (OVID) and CENTRAL
1 exp Common Cold/
2 common cold$.mp.
3 exp RHINOVIRUS/
4 rhinovir$.mp.
5 or/1-4
6 exp Ascorbic Acid/
7 ascorbic acid.mp.
8 vitamin c.mp.
9 or/6-8
10 5 and 9
EMBASE
1 exp Common Cold/
2 common cold$.mp.
3 exp Rhinovirus/
4 rhinovirus infection$.mp.
5 or/1-4
6 exp Ascorbic Acid/
7 vitamin c.mp.
8 or/6-7
9 5 and 8
We also screened the reference lists incorporated in a series of
systematic reviews of the literature published by Briggs 1984 and
Kleijnen 1989 (for the search strategies, see Kleijnen 1992) and
the papers in those studies. One of the current review authors
(HH) has a fifteen year research involvement in this topic and
has assembled a large personal reference list of papers published
in the grey literature or listed in indexing services that preceded
electronic searching. These were added to a primary database
which was then systematically screened by two review authors
(BD and Ron D’Souza - a previous review author) who worked
together to exclude duplicate entries, preliminary reports of data
more fully reported elsewhere, commentaries, editorials and
other papers which did not contain unique reports of controlled
or randomised clinical comparisons.
These two review authors then separately reviewed hard copies
or electronic abstract data on each of 84 papers, applying the
selection criteria outlined above. A final list of 62 papers was
selected, which contained unique data from one or more trials
of vitamin C and the common cold. One of the papers (Bibile
1966 cited by Kleijnen 1989) remains unassessed as we have
been unable to retrieve a copy through library orders. Twenty-six
of the 61 remaining papers failed to meet the selection criteria.
This left us with 36 papers, of which 12 contained reports of two
or more (up to six) unique study comparisons and an entry for
each comparison was made into the ’Characteristics of included
studies’ table, using the letters a, b, c, d, e and f to identify
different study comparisons within the one publication. The
review in 2004 included data from 56 distinct trial comparisons,
which was 25 more than in the original 1998 review. In four
of the papers (Anderson 1974a; Anderson 1975a; Audera
2001a; Karlowski 1975a) more than one actively treated group
was compared with the same placebo treated group. To avoid
the ’unit of analysis problem’ for which we were legitimately
criticised in the original 1998 review, where multiple active arms
were considered separately in the same meta-analysis, they were
combined as one entry which appears in the figures, identified as
the ’highest’ lettered trial that it contained.
For this 2007 update, we searched CENTRAL (The Cochrane
Library Issue 4, 2006); MEDLINE (2004 to December 2006);
and EMBASE (1990 to December 2006). In this update, the
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searches were repeated with a slightly modified EMBASE search
string.
EMBASE (DataStar)
1 common adj cold$
2 rhinovirus$
3 ascorbic-acid#.de.
4 ascorb$
5 vitamin$ next c
6 1 or 2
7 3 or 4 or 5
8 6 and 7
In the period from June 2004 to December 2006 only one new
trial conforming to our selection criteria was published (Sasazuki
2006).
M E T H O D S O F T H E R E V I E W
The circumstances and results of three small laboratory trials were
summarised in a separate table (Table 01) and were not included
in the meta-analyses with the community trials.
For the community trials, three outcomeswere selected to compare
vitamin C with placebo recipients, resulting in five meta-analyses;
the number in parenthesis refers to the respective comparison
figure in the analyses:
(Comparison 01) ’Incidence’ - the proportion of participants who
experienced one or more episodes of respiratory illness during
prophylaxis;
(Comparison 02) and (Comparison 04) ’Duration’ - mean days of
cold symptoms per illness episode (episodes occurring in trials of
prophylaxis and therapy were analysed separately); and
(Comparison 03) and (Comparison 05) ’Severity’ - mean severity
score for the illness episode (also applied separately to both
prophylaxis and therapy trials). The severity index was a
continuous variable measured in two ways in different trials: a) the
number of days that the patient was absent from work or school
or confined to bed; and b) a symptom severity score derived from
patient kept records.
A meta-analysis was conducted using Review Manager (RevMan)
software for each of these five outcomes.
A pooled relative risk (RR) of the probability of experiencing one or
more colds while taking vitaminCwas computed for the incidence
data. Due to the heterogeneity observed in this outcome across
the trials, a random-effects model in RevMan was applied to the
pooled estimate. Heterogeneity was explored both qualitatively
and using a sensitivity analysis.
The pooled mean difference (MD) in illness duration was
computed to derive an estimate of the percentage of days of
illness by which vitamin C reduced the average common cold.
Since duration of cold episodes varied appreciably across trials,
we standardised the mean values and standard deviations (SD)
obtained in each trial group, against the mean of their placebo
group. In this way, the placebo group gets value 100%, and the
difference between the vitamin C and placebo group is directly
the effect of treatment (in percentages). Because of the level of
heterogeneity observed across trials, we applied a random-effects
model to compute separate pooled estimates of the MD for two
sub-groups; adults and children.
Some trials presented the mean duration or severity of colds, but
not the respective SD. In some trials the P value for the difference
of interest was reported and the SD was calculated from it. In
case of the Anderson 1972 and Anderson 1974a and Anderson
1975a trials, Fieller’s theorem was used to estimate the SD for
individual common cold episodes from the SD values presented
in papers that were based on per person experience. In the other
trials with missing SD we estimated SD as identical with the mean
of the treatment group. This is based on the analysis, that for trials
reporting the SD, the ratio of SD to mean is on average 0.7 so that
our ratio of 1.0 used in SD-estimation is somewhat conservative.
The consequence of this is that we are putting slightly reduced
weight on our estimates of effect on these trials with missing SD
values, compared to the average.
The two different approaches to the assessment of severity were
considered separately in the meta-analysis by treating the two sets
of trials as separate subgroups. A standardised mean difference
(SMD)was computed for each pool of results to enable us to derive
a pooled estimate of the effect of vitamin C on cold severity across
all trials for which severity data were available.
The SMD method leads to quantitative results that cannot be
directly interpreted. Rather the primary statistical result of the
SMD method is the P value for the combined set.
Four factors were considered as possible explanations for the
heterogeneity observed across the results of these trials. These
were trial quality, vitamin C dosage, age of participants, and the
particular life circumstances of the participants.
To explore the role of vitamin C dosage, each study comparison
was categorised using the dose of vitamin C that active recipients
were taking on the first day of development of respiratory illness:
(1) 0.2 g/day or more, and less than 1 g/day;
(2) 1 g/day or more, and less than 2 g/day;
(3) 2 g/day or more.
This variable was assigned to each meta-analytic study entry as a
sorting variable in the RevMan software. It appears in the meta-
analyses as the ’user defined’ variable. If different study arms were
combined in the analysis to compare with a single placebo group
as part of our effort to avoid distortion of the pool estimate, the
dose value assigned to the arm receiving the highest vitaminCdose
was assigned to the combined group in the user defined variable.
Doses for individual arms that are incorporated in a combined
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arm comparison are presented in the ’Characteristics of included
studies’ table.
In the meta-analysis of duration while on prophylaxis, children
and adults were considered as separate subgroups.
In analysing dichotomous data with only a few cases in the
trial groups, the mid-P value is the most appropriate method to
calculate the P values for the differences in the treatment groups (see
p. 20-1 in Hemilä 2006a) and was used when comparing groups
with small numbers of cases. Two-tailed P values are used in this
review. We do not repeat the ’95% CI’ in parentheses when the
limits of the confidence interval are unambiguous in the context.
Assessing the role of study quality
To test the robustness of our conclusions regarding incidence and
duration, we undertook a sensitivity analysis in which we excluded
from the analysis all of the studies in which allocation concealment
was judged to be ’inadequate’.
Unit of analysis issues
In the first edition of this review we were rightly criticised for
the ’unit of analysis’ problem, as we compared several arms of a
trial to the same single placebo group, which meant that the same
placebo group was counted several times in pooling. In the current
version we have combined the respective treatment arms to a single
treatment group so that there is no inflation of participants in
the placebo groups. Miller and Carr studied twins, and this was
pointed out by a comment on the previous version. Our current
SDvalues used in the calculations are based on the SE and P values,
respectively, of paired tests, so the two trials are getting proper
weight in pooling.
D E S C R I P T I O N O F S T U D I E S
Fifty-six separate comparative studies reported in 37 publications
met the selection criteria. Twelve of these publications presented
the results of two to six different study comparisons. Included in
the selected papers are the four reports identified originally by Paul-
ing 1971a to justify his proposals for mega dose prophylaxis and
therapy (Cowan 1942; Franz 1956; Ritzel 1961; Wilson 1969).
We have used theWilson 1973a final report of his boarding school
trials rather than the preliminary communication of that group’s
first study which Pauling 1971a had available to him.
Links to the trial reports and translations can be found at www.
ltdk.helsinki.fi/users/hemila/CC/.
In Anderson 1974a, Anderson 1975a, Audera 2001a and Kar-
lowski 1975a, more than one active arm is compared with a single
placebo arm. This means that the total participants presented in
the summary analysis tables are less in the placebo groups than in
the vitamin C groups.
The 56 included trials which have contributed data to this report
fall into three distinct methodological groups.
(1) Three laboratory trials (Dick 1990; Schwartz 1973; Walker
1967) in which volunteers were intentionally exposed to known
viruses after preliminary dosage with vitaminC or placebo. As they
are small and qualitatively different from the community based
trials, they have not been included in the meta-analyses but are
presented in Table 01.
(2) Forty-two distinct community prophylaxis trials which evalu-
ated the effects of daily supplementation with vitamin C on reduc-
ing the incidence or severity or both of naturally acquired colds.
(3) Eleven community therapeutic trials that evaluated the thera-
peutic effects of high dosage vitamin C after natural common cold
symptoms had commenced.
Brief details of the circumstances, dosage, and quality assessment
of the trials are available in the ’Characteristics of included studies’
table.
M E T H O D O L O G I C A L Q U A L I T Y
Three indicators of study ’quality’ were collected on all trials.
(1) Allocation concealment in which a series of judgements based
on explicit criteria are made relating to the question whether the
assigned treatment was adequately concealed prior to allocation.
Three categories were used: A, Adequate; B, Unclear; C, Inade-
quate.
(2) The Jadad score (Jadad 1996) which requires allocation of
points out of five relating to the methodological statements in
the text about ’blinding’ of participants and investigators and the
process of randomisation as well as the reporting of trial ’drop
outs’. The Jadad scores ranged from 0 to 5.
(3) Placebo distinguishability (PD) based on evidence presented
in the publication as to the visual and taste characteristics and dis-
tinguishability between the test preparation of vitamin C (mostly
ascorbic acid) and the placebo. The two categories were: I: placebo
explicitly stated to be indistinguishable from vitamin C tablet, and
? : uncertain, no explicit comments.
Study quality was not used as an exclusion criterion, but we only
included trials in the meta-analyses which were sufficiently well
documented to enable us to assign values for each of the three
measures of study quality. Allocation concealment was used to sort
the meta-analyses when exploring possible reasons for study het-
erogeneity, and sensitivity analysis was carried out to test the ro-
bustness of the findings of the review when the meta-analyses were
confined to studies in which allocation concealment was judged
not to be inadequate.
Allocation concealment, Jadad scores and placebo distinguishabil-
ity assessments are presented in the ’Characteristics of included
studies’ table.
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R E S U L T S
1) Laboratory trials with artificially infected volunteers
Three laboratory trials were volunteer transmission studies which
are summarised in Table 01. Walker 1967 and Schwartz 1973 in-
stilled virus into the noses of volunteers who had been pre-treated
with vitamin C or placebo, whereas Dick 1990 used a more nat-
ural mechanism for transmission of a known rhinovirus. Their
volunteers were housed for a week and worked closely with volun-
teers who had been previously infected by nasal instillation of rhi-
novirus. In the Dick 1990 study, fewer vitamin C treated volun-
teers became infected and the cumulative symptom severity score
and mucus weights were significantly less (P = 0.03), although the
virus shedding was similar in both treatment and placebo groups.
Schwartz 1973 found reduced common cold severity in vitamin
C group (P < 0.02 at day 4), but no effect on symptom duration,
whereas Walker failed to report any benefit to those who took vi-
tamin C.
2) Community prophylaxis trials: incidence of colds
Comparison 01 presents the meta-analysis of the relative risk of
one or more colds developing while on prophylaxis. The entry
in the meta-analysis for Anderson 1974a represents four separate
trial arms (Anderson 1974a; Anderson 1974b; Anderson 1974c;
Anderson 1974d) in which different vitamin C dosages ranging
from 0.25 to 2 g/day were compared with one placebo group.
Thus the 30 entries in the figure represent 33 vitamin C arms in
trials.
The studies summarised here represent 11,350 participants, of
whom 6135 used vitamin C for periods ranging from two weeks
to five years, and the RR of developing a cold while taking vitamin
C prophylaxis in individual trials ranging from 0.39 to 1.36. The
pooled RR for all trials using a random-effects model was 0.96
(95% CI 0.92 to 1.00).
Heterogeneity of results
Among all the 30 entries included in Comparison 01 there is
substantial heterogeneity, as indicated by the chi-square test (P =
0.03) and the high I-square (I2) value (36%).
Five of the 30 comparisons recorded statistically significant (P <
0.05) protection favouring the vitamin C group: Peters 1996a (RR
0.39), Peters 1993a (RR 0.50), Ritzel 1961 (RR 0.55), Charleston
1972 (RR 0.77), and Anderson 1972 (RR 0.91). Five other tri-
als recorded a non-significant RR ≤ 0.80 (Himmelstein 1998a;
Moolla 1996a; Moolla 1996b; Peters 1996b; Sabiston 1974).
None of the 30 comparisons significantly favoured the placebo.
Of the nine relatively small trials with RR < 0.8, four were with
marathon runners (Himmelstein 1998a; Moolla 1996a; Peters
1993a; Peters 1996a), two others were in sedentary controls for
marathon runners (Moolla 1996b; Peters 1996b), one was with
students in a skiing school in the Swiss Alps (Ritzel 1961), one
with Canadian army troops on subarctic operations (Sabiston
1974), and one with staff and students at Glasgow University, UK
(Charleston 1972).
A subgroup analysis is shown in Comparison 01 in which the six
studies which involved marathon runners, skiers, and Canadian
soldiers in a subarctic exercise were moved to a separate subgroup:
participants with heavy acute physical activity (RR 0.50; 95% CI
0.38 to 0.66). This resulted in two distinct groups of trials which
were significantly different from each other in their pooled esti-
mates of effect. Furthermore, the two subgroups were homoge-
neous within the two pools, as indicated by the high p-values in
the chi-square test, and the zero values for the I2s.
All of these six studies on physical or cold stresses or both, were
randomised controlled trials. In three of them, vitamin C dose
was less than 1 g/day so that the benefit in this subgroup is not
explained by particularly high doses, but by the particular condi-
tions.
To test the effect of study quality on the findings, we undertook
sensitivity analysis in which we removed from the meta-analyses
the seven study entries inwhich allocation concealmentwas judged
inadequate. Total pooled RR was 0.97 (95% CI 0.94 to 1.01),
with the pooled RR value for the physical or cold or both stress
studies at 0.53 (0.37 to 0.76). Thus, the effect of study quality
as assessed by allocation concealment did not appreciably change
either the quantitative estimates of the pooled results, or the qual-
itative conclusions.
3) Community prophylaxis trials: duration of colds
The meta-analysis in Comparison 02 on duration of colds which
developed while participants were taking prophylaxis was divided
into two subgroups: adults and children. For adults there were 18
entries representing 22 trial arms (four separate trial arms in one
entry for Anderson 1974a and two for Karlowski 1975a) and 7242
episodes of illness, and for children there were 12 trial comparisons
including 2434 episodes of illness. The division into subgroups of
child and adult trials was carried out for two reasons: a) children
have substantially higher incidence of colds reflecting differences
in immune systemmaturity, and b) children are on average smaller
so that a fixed dose corresponds to a greater dose per weight.
Quite consistent benefit was seen in duration of colds, but the
effect was greater in children. For children, the pooled effect was
a 13.6% (95% CI 5.6% to 21.6%) reduction in common cold
duration, and for adults, the pooled effect was an 8.0% (3.0% to
13.1%) reduction in duration. The chi-square test for trial hetero-
geneity was not statistically significant in either of the groups.
In four of the 30 trials (Carr 1981b; Charleston 1972; Ludvigsson
1977a; Ritzel 1961) the difference in episode duration was statis-
tically significant within the trials themselves.
All but four of the 30 comparisons (Carr 1981a; Himmelstein
1998a; Peters 1993a; Wilson 1973b) recorded a point estimate
favouring the vitamin C group.Wilson 1973b used only 0.2 g/day
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vitamin C, which is the smallest dose in Comparison 02. Carr
1981a examined twins living together, whereas the Carr 1981b
trial examined twins living apart; it is possible that the substan-
tially divergent result in these twin groups is related to the living
conditions, for example, those living together might conceivably
have exchanged or confused their tablets.
In contrast to all the other trials, Himmelstein 1998a recorded
a statistically significant increase in common cold duration in
marathon runners taking vitamin C (though incidence was de-
creased in the vitamin C takers, see Comparison 01). There was an
extreme and divergent drop-out rate in the Himmelstein 1998a
trial. They started with 52 marathon runners in two groups, but
42% (22 of 52) of the vitamin C group, and 75% (38 of 52) of
the placebo group dropped out during the trial (P = 0.003). The
apparent increase in common cold duration might be related to
biases caused by the high and significantly divergent drop-out rate.
In a sensitivity analysis we excluded the Himmelstein 1998a trial
from the adult subgroup, and there was a substantial reduction
in the heterogeneity (P = 0.5 in the chi-square test; and I2= 0%),
and the test for overall effect in this adult subgroup became even
more significant (P = 0.0002), yet the difference in pooled effect
for adults was minimally changed: 7.7% (3.7% to 11.8%).
The great majority of the trials in Comparison 02 used 1 g/day of
vitaminC and therefore a systematic examination of possible dose-
dependency across the trials was not feasible. We used sensitivity
analysis to test the possible role of low vitamin C doses in affecting
the estimate of effect in the child subgroup. When we removed
the trials using less than 1 g/day of vitamin C (Miller 1977b;
Miller 1977c; Wilson 1973a; Wilson 1973b), the pooled estimate
of benefit was increased to 18% (7% to 30%).
In seven trials we imputed the SD values assuming that SD is equal
to themeanof the group (Briggs 1984;Coulehan1974a;Coulehan
1974b; Coulehan 1976; Peters 1996a; Peters 1996b; Pitt 1979).
Whenwe excluded these in a sensitivity analysis, the pooled results
indicated slightly greater effect by vitamin C supplementation:
adults, 9.3% (3.0% to 15.6%); children, 14.3% (4.6% to 24.1%).
Furthermore, the Anderson 1974a trial used two placebo arms
which were significantly discordant (Hemilä 2006asee p. 40). In
this Cochrane review we used placebo arm #4 for which baseline
data were close to the vitamin C arms. As a sensitivity analysis we
excluded the Anderson 1974a, but the pooled effect for adults was
minimally changed: 8.4% (2.6% to 14.2%).
Finally, to test the effect of study quality on the findings, we un-
dertook sensitivity analysis in which we removed from the meta-
analyses the studies in which allocation concealment was judged
’inadequate’. The total pooled benefit for adults was 7% (1% to
13%), and the pooled benefit for children was 13% (4% to 23%).
Thus, the study quality as assessed by allocation concealment did
not affect the conclusions.
In summary, this meta-analysis of duration of colds experienced
while participants were taking prophylaxis demonstrated amodest
but consistent and statistically significant benefit to the vitamin C
supplemented participants which was greater in children than in
adults.
4) Community prophylaxis trials: severity of colds
Two types of measures of the severity of illness were available.
Seven entries in Comparison 03 present the results of 10 vitamin
C study arms in which severity was measured by ’days confined
to home’ or ’days off work or school’ (subgroup 1). This included
5066 respiratory episodes in adults and children. The large scale
trial by Anderson 1972 reported a statistically significant protec-
tion by vitamin C. The pool as a whole found a modest, but sig-
nificant reduction. This subgroup exhibited highly significant het-
erogeneity across the subgroup as measured by the chi-square and
I2 tests.
Subgroup 2 in Comparison 03 presents the results of symptom
severity scores in eight trials. The large scale trial by Pitt 1979
found a statistically significant, but small, 5% reduction in severity
score. Here too, the subgroup exhibited highly significant hetero-
geneity across the subgroup as measured by the chi-square and I-
square tests. Himmelstein 1998a found substantially greater sever-
ity in vitamin C administered marathon runners, but as noted
above, this trial had a particularly high and divergent drop-out
rate, and the study groups may be biased. In a sensitivity analysis,
excluding the Himmelstein 1998a trial substantially reduced the
heterogeneity among the remaining seven trials (P = 0.5 in chi-
square test, and I2 = 0%), the overall effect significantly favouring
vitamin C in this subgroup (P = 0.003).
Themeasures of ’severity’ that have beenused in the trials are highly
variable and we used the standardised mean difference which nor-
malises the results to standard deviations. Therefore the pooled
results of Comparison 03 are not practically useful, rather, the
significance level is of main importance in this case; P = 0.02 for
the studies that assessed days confined to home or off work or
school, and P = 0.16 for studies which used severity scores, and P
= 0.004 when the two pools using different measures of severity
were combined.
Sensitivity analysis using allocation concealment as the excluding
variable failed to change appreciably the standardised mean dif-
ference that was estimated from the whole pool.
In summary, there was inconsistent evidence of the benefit of vi-
tamin C on the severity of illness episodes that were experienced
during prophylaxis. Such benefit with respect to days confined to
home or off work or off school was statistically significant, but
relatively slight in absolute terms which can be seen by viewing
the original mean values in the figure.
5) Community therapeutic studies: duration of colds when
treatment commenced after common cold symptoms began
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Themeta-analysis presented in Comparison 04 contains seven en-
tries that incorporate data from 11 different trial arms involving
3294 cold episodes where participants initiated supplementation
at the onset of cold symptoms. Audera 2001a contains three differ-
ent vitamin C dosage arms, while Anderson 1974e and Anderson
1975a each contain two different vitamin C dosage arms. These
are detailed in the ’Characteristics of included studies’ table.
The pooled result for these therapeutic trials, unlike that seen in
the prophylaxis trials, did not exhibit a consistent difference of vi-
tamin C from placebo in the variety of therapeutic protocols that
were used. The large trial by Anderson 1974e found statistically
significant but modest benefit on severity but this was counterbal-
anced by the negative results in other trials.
The statistically significant Anderson 1974e entry combined two
different dosage arms. Anderson 1974e administered 4 g/day, and
Anderson 1974f administered 8 g/day on the first day of illness
only. Themean duration of illness episodes for those in the 4 g/day
arm was 3.17 days, while that for 8 g/day arm was 2.86 days com-
pared with the duration in the placebo group #4 of 3.52 days. This
1974 trial was bedeviled, however, by the fact that the investigators
originally intended to compare results with two separate placebo
groups. One of the placebo groups (#6) had substantial baseline
differences when compared with the six vitamin C groups. The
comparisons presented here are with the placebo group #4 that
was much closer to the vitamin C groups with respect to baseline
data (seeHemilä 2006a). If comparisons had been made with the
placebo group #6 or a combination of the two placebo groups
as the investigators had originally intended, the benefits would
have beenminimised as themean episode duration for the placebo
group #4 was 3.52, and for placebo group #6 was 2.83. Neverthe-
less, notwithstanding the placebo group problem, the proportion
of ’short colds’, that lasted for only one day was larger in the 8
g/day group (46%; 222 out of 483) compared with the 4 g/day
group (39%; 164 out of 417) (P = 0.046), consistent with the
possibility of therapeutic benefit at the higher dosage (see p. 42 in
Hemilä 2006a).
Tyrrell 1977, Elwood 1977 and Audera 2001a, Audera 2001b,
Audera 2001c failed to show an effect on duration. Tyrrell evalu-
ated males and females separately using a dosage of 4 g/day for the
first 2.5 days of illness (total 10 g), Elwood evaluated males and
females separately using a dosage of 3 g/day for the first 3.3 days
of illness (total 10 g), and Audera evaluated 3 g/day over the first
three days (total 9 g).
Sensitivity analysis in which allocation concealment was used as
the excluding variable once again failed to change the conclusions
of this meta-analysis.
In summary, the data from the therapeutic trials do not provide
convincing evidence of reduced duration with the protocols that
have been tested and the apparent benefits from the use of an 8 g
single dose immediately after the onset of cold symptoms may be
regarded as ’equivocal’.
6) Community therapeutic studies: severity of cold episodes
when treatment commenced after common cold symptoms be-
gan
Comparison 05 has four entries which represent eight trial arms
that included 2753 separate respiratory episodes for which cold
severity was assessed. (Anderson 1974a and Anderson 1975a con-
tain two vitamin C arms and Audera 2001a, Audera 2001b, Au-
dera 2001c contains three different vitamin C arms). As with the
prophylaxis studies, we have separated the measures of severity
into two different subgroups (1) days confined to home, off work
or school, and (2) symptom severity scores, and analysed the sub-
groups separately and together.
In the first subgroup, the only comparison which revealed
marginally significant benefit to those taking vitamin C was that
for Anderson 1975a. In both vitamin C arms, participants took
1.5 g/day for the first day of the common cold and 1 g/day for the
following four days (total 5.5 g). Anderson 1974e andTyrrell 1977
found no meaningful difference between vitamin C and placebo.
In the second group, the Audera 2001a, Audera 2001b, Audera
2001c trial similarly found no meaningful difference between vi-
tamin C and placebo groups.
Once again, the conclusions did not change when carrying out
sensitivity analysis based on allocation concealment.
In summary, therapeutic vitamin C supplementation has shown
no convincing effect on common cold severity with the protocols
that have been used.
7) Adverse effects from high dose vitamin C intake
Seven investigators of large prophylaxis trials recorded data on
symptoms which participants attributed to the medication they
were using.
Trials involving altogether 2490 recipients who had used more
than 1 g daily of vitamin C during prophylaxis compared with
2066 who took a placebo recorded these data. Altogether 5.8% of
the vitamin C recipients reported adverse symptoms which they
attributed to the medication compared with 6.0% of those who
were taking placebo (data not shown). No serious symptoms were
reported.
D I S C U S S I O N
The term ’the common cold’ does not denote a precisely defined
disease, even though the illness is familiar to most of us. It is a
complex of conditions caused by a broad range of viruses and oc-
casionally bacteria. There is no unanimously accepted definition.
Instead, various different operational definitions have been used,
usually defining a minimum set of symptoms. This variation in
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outcome definition could contribute to heterogeneity, although
we are not able to explore this.
Although the importance of the placebo-effect has been challenged
(Hrobjartsson 2001; Hrobjartsson 2005) we considered that with
the expected small effects of vitamin C, and the greatly subjective
outcome definitions, only placebo-controlled trials could yield in-
formation of adequate rigour to meet our study objectives. Most
of the trials analysed in this review were reported to be double-
blind, but that was not used as a selection criterion. Also we did
not restrict the review to trials using random allocation and there
are some trials included which used alternate allocation. Sensitiv-
ity analyses indicated that excluding trials which had inadequate
allocation concealment did not alter our conclusions.
Despite the variation in methodology and the substantial hetero-
geneity in results from this large number of trial results carried out
over a sixty year period, a rather coherent story emerged from the
review.
Effect on common cold incidence
Consistent with earlier reviews (Hemilä 1997a; first version of
this Cochrane Review (Douglas 1998a)) we found no convincing
reduction in commoncold incidence in the prophylaxis trialswhen
the subgroup of marathon runners and skiers and soldiers on sub-
arctic operations were excluded from the trial pool (RR 0.98; 95%
CI 0.95 to 1.00).
A previous meta-analysis identified three trials with participants
under severe acute physical stress which had found significant
benefit from vitamin C supplementation (Hemilä 1996b). The
more recent trials by Peters 1996a, Moolla 1996a and Himmel-
stein 1998a have reinforced and extended those observations. The
small study reported by Sabiston 1974 which involved Canadian
troops engaged in brief exercises in subarctic conditions, found a
substantial reduction in common cold risk. It is noteworthy that
all six studies in this group involved brief exposure to high physical
or cold stress or both types of stress, and the doses of vitamin C
were uniformly not particularly high.
One of the review authors (Hemilä 1997a) has also previously
drawn attention to the possibility that some of the earlier bene-
fits observed in low dose studies and controlled trials without a
placebo, which were ruled ineligible for this review (Baird 1979;
Glazebrook 1942), might be a consequence of suboptimal dietary
intakes in British males when the studies were carried out. This
might also explain the significant benefit in the Charleston 1972
trial though participants in that study were single-blinded and not
randomised. Few of the recent trials have estimated the dietary
intakes of vitamin C, but we cannot ignore the fact that vitamin C
is an essential nutrient and all participants in the trials had regular
intakes of this substance at some level, some of them with lower
levels than others. Four UK trials also found a reduction in the in-
cidence of recurrent colds during the study period inmales (pooled
RR 0.54; 0.40 to 0.74) but not in females (Hemilä 1997a). A
recent UK trial found reduction in recurrent colds in a nine week
trial in both sexes (RR 0.13; 0.03 to 0.53) (see p. 47 in Hemilä
2006a; Van Straten 2002).
The large, well conducted trial by Anderson 1972 reported a sta-
tistically significant but quite small reduction in common cold in-
cidence (RR 0.91; 0.85 to 0.98). This trial was conducted during
winter in Toronto, Canada, and participants were selected on the
basis of having had problems with colds during previous winters.
A cold Canadian winter might be a partial explanation for the ben-
efit in this trial if it is true that cold as well as physical stress makes
a prophylactic benefit for vitamin C more likely. Furthermore,
as regards the possible interaction between supplementation and
dietary vitamin C levels, this Anderson 1972 trial is interesting
as the investigators found a 48% reduction in ’total days indoors’
among participants in the vitamin C group who consumed < 3
oz of fruit juice, whereas vitamin C reduced total days indoors
by only 22% among those who consumed more juice. A similar
modifying effect with fruit juice was found in the therapeutic trial
by Anderson 1975a (see p. 35 in Hemilä 2006a).
Effect on common cold duration and severity: prophylaxis tri-
als
Both in adults and in children, regular vitamin C supplementa-
tion resulted in a statistically highly significant reduction in the
duration of respiratory episodes that occurred during the prophy-
lactic supplementation period. For children, the pooled estimate
was 13.6%, and for adults it was 8.0%.
Although these findings point to a definite physiological effect
from prophylactic vitamin C on common cold duration, the prac-
tical significance of these findings is less convincing. It would not
seem reasonable to ingest vitamin C regularly in the mega-dose
range throughout the year if the only anticipated benefit is to rather
slightly shorten the duration of colds which occur for adults two
or three times per year. Our pooled estimate suggests that long
term supplementation might result in an upper estimate average
reduction of annual common cold morbidity from about 12 days
(Douglas 1979) to about 11 days per year for adults. For children
under 12, who experience colds more frequently (on average for
this age, the upper estimate could be as high as 28 days of cold
morbidity annually), our pooled estimate of benefit suggests that
long term prophylaxis might be associated with an average reduc-
tion in four symptom days from about 28 days to 24 days per year
per child. Such a benefit is not trivial, but is it worth the cost of
long term prophylaxis, and could an equivalent benefit perhaps be
achieved in children through therapeutic supplementation alone?
In light of the consistent effect of vitamin C on the duration of
colds, an obvious question is whether there might be dose depen-
dency, as suggested in a previous overview (Hemilä 1999a) that
might translate to a benefit when vitamin C is used therapeutically.
However, across the available pool of trials, duration would appear
to be more determined by the nature of the participants than by
dose. There are few trials that have used more than 1 g/day in the
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child and adult groups separately. Nevertheless, Karlowski 1975a
and Coulehan 1974a used two different doses within the same tri-
als, that is, with the same outcome definitions. Karlowski’s paper
shows that for adult, 6 g/day was associated with a double benefit
compared with 3 g/day, and Coulehan found that for school chil-
dren, 2 g/day caused about twice the benefit of 1 g/day (Hemilä
1996a; Hemilä 1999a). Although these findings do not establish
dose dependency, they support the case for examination of higher
doses.
Regular vitamin C prophylaxis also led to some decrease in severity
when measured as days indoors or days off work or school, but the
effect was not unambiguous on severity score scales (Comparison
03). These measures of severity are substantially more heteroge-
neous than the measures of symptom duration and the number of
trials reporting data pertinent to ’severity’ is small.
On the issue of the severity of colds, the Pitt 1979paper is of further
interest. This was a randomised placebo-controlled double-blind
trial with 674 marine recruits during an eight week period using
2 g/day of vitamin C. There was no difference in common cold
incidence and only a 2% reduction in duration of colds and 5%
reduction in severity (P = 0.023). However, eight of the recruits
developed pneumonia as a sequel to their colds and only one of
these was in the vitamin C group (P = 0.044; see Hemilä 2004a;
Hemilä 2007). Thus, in addition to the common cold, vitamin C
might also affect other respiratory infections either independently
of colds, or as complications of colds (Hemilä 1999b). It is also
worth noting that on the basis of subjective observations, 6% (40
out of 674; P = 0.013) of Pitt 1979 participants correctly inferred
vitamin C or placebo tablets even though the trial was double-
blinded (see p. 26 in Hemilä 2006a).
Effect on common cold duration and severity: therapeutic tri-
als
Since the prophylaxis trials have relatively consistently shown that
vitamin C affects duration and, to some extent, the severity of
the common cold without changing their incidence in the normal
population, it might seem rational to administer vitamin C ther-
apeutically, starting immediately after the first symptoms. But the
therapeutic trials that have evaluated this have mostly been nega-
tive (Comparisons 04 and 05). The pooled estimates for duration
and severity do not find any difference between vitamin C and
placebo.
Technically the therapeutic trials are in several ways more com-
plicated than regular supplementation trials. If the timing of sup-
plementation initiation, the duration of supplementation, or the
dosage affect the size of the benefit, false negative findings might
result from inappropriate study protocols.
Cowan 1950 used a therapeutic dose of about 3 g/d in the first two
days of illness with no effect on duration. Elwood 1977, Tyrrell
1977, and Audera 2001a used a three day supplementation, and
these three trials found no effect from vitamin C; however, in their
therapeutic trial, Tyrrell 1977 found a 40% reduction (P = 0.04)
in the incidence of recurrent colds in men during the trial (Hemilä
1997a). A five-day therapeutic trial by Anderson 1975a found a
reduction in ’days spent indoors per subject’ because of illness by
25% (P = 0.05) in the vitamin C group (1 to 1.5 g/day). Also,
using a five-day therapeutic supplementation of 3 g/day in a 2
x 2 factorial design trial, Karlowski 1975c found that colds were
0.73 days shorter (P = 0.10; see Hemilä 1996a). These findings
are consistent with the possibility that three days might be too
short a time for vitamin C to produce unambiguous benefits, and
it seems that future therapeutic trials should use supplementation
for longer than three days.
It is also possible that the rapidity of initiation of vitamin C sup-
plementation may have an impact on the effect. Asfora 1977 gave
the same participants either vitamin C (6 g/day for five days) or
other medications (aspirin, etc.) during different common cold
episodes, but not in a double-blinded fashion. When treatment
started within 24 hours of the onset of symptoms, the mean du-
ration of vitamin C treated colds was 3.6 days, whereas the dura-
tion was 6.9 days with the other medications (−48%; see p. 48 in
Hemilä 2006a). However, if vitamin C supplementation was ini-
tiated later than 24 hours following the onset of symptoms, there
was no meaningful benefit. Regnier 1968 also concluded from his
therapeutic study that “the sooner the better” and “vitamin C ad-
ministration is not effective when started on the third or fourth
day or later in the viral infection.” Anderson 1974f found a ben-
efit from an 8 g vitamin C dose when administered only on the
first day of illness, which also is consistent with the possibility that
rapid initiation of supplementation may be essential. In several
therapeutic trials, tablets were given to participants to be taken at
home so they could start taking them as soon as they experienced
the first symptoms of what they anticipated would be a cold (An-
derson 1975a; Audera 2001a; Cowan 1950; Elwood 1977; Tyrrell
1977). In the Karlowski 1975c trial “if a cold developed, the vol-
unteers were instructed to return to have their symptoms and clin-
ical observations recorded and to receive supplemental study drug
to be taken” and thus there was an unknown delay between the
onset of symptoms and the initiation of treatment. Tebrock 1956
carried out their trial “on participants reporting to several out-
patient industrial clinics under the supervision of the physicians
conducting the study” indicating delay between symptom onset
and treatment. In the briefly described Abbott 1968 trial, it seems
that the tablets were administered by the doctors taking part in the
trial and the average time between symptom onset and treatment
initiation remains unknown. Consequently, even though the time
between symptom onset and treatment initiation may affect the
benefit of vitamin C supplementation, the data on this factor is
limited and there are many other differences between the trials.
The possible larger effect observed using 8 g compared with 4 g as a
single dose in the Anderson 1974f trial and the dose dependency in
the Karlowski 1975a trial (Hemilä 1996a; Hemilä 1999a) suggest
that future therapeutic trials with adults should use doses larger
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than 4 g per day. Similarly, the greater reported benefit of 2 g/day
than 1 g/day in the prophylactic Coulehan 1974a trial suggests
that therapeutic trials with children should use doses larger than
2 g per day.
Finally, none of the therapeutic trials examined the effect of vita-
min C on children, although the effect of prophylaxis on duration
has been substantially greater in children compared with adults,
and children have substantially higher incidence of acute respi-
ratory tract infections. Furthermore, although a tablet is practi-
cal and the most common form of administering vitamin C, it is
worth noting that administering vitamin C powder directly into
the nose has also been proposed (Gotzsche 1989).
Laboratory studies
The summary evidence from the three experimental studies, which
differed in their method of exposing volunteers to the infecting
virus, is instructive. The study by Dick 1990, which has only been
reported in conference proceedings, paid careful attention to the
severity of the colds experienced by those who acquired them from
fellow volunteers, who had been inoculated with a known rhi-
novirus. They also found that in these more natural circumstances
of acquiring the virus, less, but not significantly less, volunteers
on vitamin C developed cold symptoms but demonstrated similar
viral shedding to the placebo group. The tantalisingly fragmen-
tary descriptions of the Dick studies indicate a biological effect
of high dose vitamin C on the nature and course of symptoms
encountered. The findings appear to confirm the view from the
community prophylaxis studies that the protective benefit from
vitamin C comes into play after the virus has become established.
Heterogeneity in the effects of vitamin C
A major finding of Comparison 01 was heterogeneity in the ef-
fect of vitamin C supplementation on common cold incidence.
Furthermore, Anderson 1972 found about an 8% increase in the
proportion of participants who were ’not ill during the trial’, ’not
confined to the house’, and ’not off work’ in the vitamin C group.
Accordingly, about 1 participant in 12 benefited from vitamin C
supplementation in this particular setting (number needed to treat
to benefit (NNTB) 12). It is noteworthy, however, that partici-
pants in this Canadian trial were asked not to enrol in the trial un-
less they normally experienced at least one cold in the wintertime,
and in this respect the participants do not represent the average
population. Coulehan 1974a studied Navajo school children and
found a 16% higher proportion of children in the vitamin C group
who were ’never ill on active surveillance’ by a medically trained
clerk or the school nurse (NNTB 6 in this particular setting; see
p. 44 in Hemilä 2006a). Thus, these two trials suggest that some
participants may benefit, even though there is no marked effect
from vitamin C on the average common cold incidence. Further-
more, evidence of heterogeneity was also found in an analysis of
the effect of vitamin C on pneumonia incidence (Hemilä 2007).
In close parallel with vitamin C, lipid-soluble vitamin E is inter-
esting as these two antioxidants interact; vitamin C reduces oxi-
dised vitamin E levels (see Hemilä 2006a). Therefore heterogene-
ity in the effect of vitamin E on common cold incidence (Hemilä
2006b) and on pneumonia incidence (Hemilä 2004b) is also rel-
evant when considering the plausible heterogeneity of vitamin C
effects.
If the effects of daily vitamin C supplementation vary substantially
between different subpopulations, the heterogeneity of the effect
evidently means a need for a careful consideration of goals when
planning new trials. Assuming heterogeneity, further trials should
try to identify and characterise the population groups or living
conditions in which vitamin C might be beneficial, rather than
re-examining the effects on ordinary Western people for whom
the trials already available have not found any substantial overall
benefits from daily supplementation. Also, the notion that various
factors may modify the effects of antioxidants is fundamentally
important in restricting broad generalisations from individual tri-
als, irrespective of whether the finding is positive or negative and
whether or not the trial is large and carefully conducted.
Safety of vitamin C
None of the vitaminCcommoncold trials that reported on adverse
effects found evidence that vitamin C might be harmful in doses
that were tested.
In general, vitaminC is considered safe in doses up to several grams
per day and although there has been speculation bout the potential
harms of large doses it has been shown to be unfounded (Dykes
1975; Hemilä 2006a). For example in a recent pharmacokinetic
study, participants were administered up to 100 g of vitamin C
intravenously within a few hours without any reported adverse
effects, indicating the safety of such a large dose in healthy people
(Padayatty 2004). Bee 1980 proposed 10 to 15 g/day for treating
colds and Cathcart 1981 reported that he had orally administered
over 30 g/day vitamin C to common cold patients, which indi-
cates the safety of such high doses, although their uncontrolled
observations do not provide valid evidence of benefit. There are
few reports of severe harm caused by high-dose vitamin C ad-
ministration and, for example, the death of a 68 year old African
American man was not attributed to intravenous injection of 80 g
of vitamin C on two consecutive days per se but to his coincident
glucose-6-phosphate dehydrogenase deficiency (Campbell 1975).
Pauling’s contribution
Among the four trials included in the Pauling 1971a meta-anal-
ysis, the largest dose, 1 g/day, was used by Ritzel 1961. Pauling
based his optimistic quantitative expectations on this rather small
and brief trial. Ritzel found significant reduction in the incidence
(−45%) and duration (−31%) of colds, and Pauling derived a
combination of the duration and incidence, which he labelled ’in-
tegrated morbidity’ referring to the total sickness days per person
during the trial.
The ’integrated morbidity’ was reduced by 61% in the Ritzel trial.
Pauling 1971a used these Ritzel findings to extrapolate the effects
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of vitaminC to a broader community. The present analysis suggests
that ’integrated morbidity’ is not a good outcome measure, since
the effects on incidence and duration/severity seem to have quite
different patterns, though in the case of the Ritzel study, they
moved together.
Furthermore, Ritzel carried out his trial with school children in a
skiing school in the Swiss Alps, and such children are not a repre-
sentative selection of the general population, even though techni-
cally the trial was randomised, double-blinded and placebo-con-
trolled. In our analysis, Ritzel’s trial is included in the group of tri-
als exposed to short lived severe acute physical stress or cold or both
environmental stresses which highlight the special character of this
trial. Thus, it was not a misjudgment by Pauling 1971a to put
the greatest weight on this randomised double-blinded placebo-
controlled trial, but his error was to extrapolate the findings to the
general population (see p. 35-6 in Hemilä 2006a).
Pauling’s vigorous advocacy was undoubtedly the stimulus for a
wave of good trials, which now enable us to better understand the
rather confusing role that this substance plays in defence against
the common cold. Significant uncertainties still persist, which fur-
ther research could help to elucidate.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The lack of effect of prophylactic vitamin C supplementation on
the incidence of the common cold in normal populations throws
doubt on the utility of this wide practice. In special circumstances,
where people are engaged in extreme physical exertion or exposed
to significant cold stress or both the current evidence indicates that
vitamin C supplementation may have a considerable beneficial
effect, but caution should be exercised in generalising this finding
that is mainly based on marathon runners.
The prophylaxis trials found an 8% reduction in common cold
duration in adults, and a 13.6% reduction in children, but the
practical relevance of these findings is open, since the therapeutic
trials carried out so far have not found benefits and this level of
benefit probably does not justify long term prophylaxis in its own
right.
In summary, on the basis of our analysis, there seems no justifi-
cation for routine mega-dose vitamin C supplementation in the
normal population. Prophylaxis may be justified in those exposed
to severe physical exercise or cold stress or both. So far, therapeutic
supplementation has not been shown to be beneficial.
Implications for research
Considering the findings from our analyses, it does not seem
worthwhile to carry out further regular prophylaxis trials in the
ordinary population. However, further research in people exposed
to heavy exertion and cold stress could increase our understanding
of the role of vitamin C. The findings in marathon runners, skiers
and soldiers operating in sub-arctic conditions warrant further re-
search.
None of the therapeutic trials carried out so far have examined
the effect of vitamin C on children, even though the prophylaxis
trials have found substantially greater effect on duration in chil-
dren. In view of the greater incidence of respiratory infections in
children, such therapeutic trials are warranted, especially where
there is known to be sub-optimal dietary intake of vitamin C.
The findings in the Anderson 1974 studies on the therapeutic use
of very high doses of 4 g and 8 g on the day of onset of respiratory
symptoms are tantalising and deserve further assessment in light of
the uncertainties raised by the problems with the placebo groups
in that important study.
N O T E S
Full text versions of references which are available either free or
from the publishers’ databases can be accessed via the home page
of the contact author, Harri Hemilä (www.ltdk.helsinki.fi/users/
hemila/CC/).
F E E D B A C K
Flaws in statistical analysis?
Summary
There appear to be several instances where there is considerable
overlap between studies, but they are treated as independent stud-
ies as far as themeta-analysis is concerned. For example, the Ander-
son 1974, 1974a, 1974b studies seem to be treated as independent
in graph (comparison 01, outcome 04), but the control groups
seem identical, and 275 people in the treatment group seem the
same in each study. The effect is to inflate the value of this study.
Indeed, the difference between the treatment groups for Anderson
1974a, 1974b (33 new people, *all* apparently with one or more
respiratory episodes) raises further issues.
I certify that I have no affiliations with or involvement in any
organisation or entity with a direct financial interest in the subject
matter of my criticisms.
Author’s reply
In the new edition of the review we have avoided this problem
described above by combining all trial arms that were compared
with the one placebo group into one trial arm for purposes of the
meta-analysis
Reply supplied by the authors of the review.
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Contributors
David Wooff
Unit of analysis issues
Summary
Further to David Wooff ’s comment, I suspect there may be other
statistical flaws in this review that could be placed under the head-
ing, ’unit of analysis errors’.
At least one study (Lugviggson) appears to be a cluster randomized
trial, yet there is no discussion of the possible over-weighting of
this study when naively included in the meta-analyses.
At least two studies appear to be twin studies (Carr and Miller).
Should the matching be taken into account in the analysis, in a
similar way to a simple cross-over trial?
The particular meta-analysis for ’Mean symptom days per person’
in the comparison ’VitaminC1Gdaily ormore vs placebo’ worries
me considerably. Of the six studies (10 contributions) included
in this analysis, I suspect that at most two are free of unit of
analysis errors of various kinds. Thismakes it a wonderful teaching
example, but for the wrong reasons.
I certify that I have no affiliations with or involvement in any
organisation or entity with a direct financial interest in the subject
matter of my criticisms.
Author’s reply
Ludvigsson writes explicitly “Every class was divided at random
into two groups.” In our opinion this statement means that Lud-
vigsson was taking one class and he divided the participants of
that one class into to two groups ’at random,’ and then he went
to another class and similarly randomized the second class. We
disagree that cluster randomisation applied here.
As to the two small twin trials: Miller 1977 explicitly stated that
“analysis of the paired comparisons…” so we conclude their SE
values in their main table are based on paired t-test, event though
this is not explicitly stated in their methods; Carr 1981 explic-
itly stated “the results for the six summary cold variables of the
paired analyses of variance between active and placebo groups are
shown…” so we conclude their P-values refer to paired analyses.
In any case, the mean difference between the groups is the same
whether we calculate difference of means or mean of paired differ-
ences. Failure to take into account the pairing of data would mean
that wewould be over-conservative in our estimate of the precision
of any effect, but it is unlikely that this issue would anyway have
influenced our conclusions in a meaningful way.
In the current review we have not used as an outcome variable
mean symptom days per person but have concentrated on mean
symptom days per episode.
Reply supplied by the Authors of the review.
Contributors
Julian Higgins
Doses too small
Summary
One gram daily is a small dose. Most mammals make 3 or more
grams in their livers. Any practitioner of orthomolecular medicine
knows that a minimum of several grams a day is needed to surely
prevent a cold, and as much as 20 grams to cure one in progress.
Not one trial in your RCT’s qualifies.
I certify that I have no affiliations with or involvement in any
organisation or entity with a direct financial interest in the subject
matter of my criticisms
Author’s reply
The practitioners of orthomolecular medicine have not to our
knowledge published any controlled trial evidence on which this
comment is based. As we have said in the review, there is no rea-
sonable doubt that vitamin C supplementation plays some bio-
logical role in defence, and there is tantalising evidence from the
Anderson 1974 study that a single therapeutic dose of 8 grams at
commencement of a cold may have had a useful therapeutic effect.
We believe there is a case for rigorous evaluation of the possibility
that very large doses (of the order of 8 g daily in adults for periods
up to five days after the onset of symptoms) could produce benefits
that were not seen at lower doses.
In view of the greater propensity of children to catch colds and
the greater benefits observed in the child prophylaxis studies, this
may be the group in which to explore this approach (with an ap-
propriately pro-rated dose for weight). We add however a caution.
Although studies in which doses of 1 or 2 g daily of vitamin C
have been used for several months have not produced convincing
evidence of adverse effects to the volunteers, dosage of the kind
discussed here needs to be carefully monitored for adverse effects
- especially in children.
Reply supplied by the Authors of the review.
Contributors
Reuven Gilmore
Vitamin C for preventing and treating the colds
Summary
This paper by Hemila and Douglas is highly misleading. Two
fundamental scientific errors invalidate the conclusions of their
review.
Their first error is the dose range: the doses employed are too small.
Treatment of disease requires pharmacological doses of vitamin C,
in the range 10 to 200 g per day [Cathcart, Medical Hypotheses,
7, 1359-76]. Prevention of disease requires a minimum of 2.5 g
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per day, in divided doses, to establish a dynamic flow through the
body. In defending their review, Hemila and Douglas cite Levine
[Levine et al. JAMA, 1999, 281,1415-23] as showing that the
body is saturated by a dose of 0.5 g per day: this finding has been
discredited. A more recent paper by Levine and colleagues shows
that the body is not saturated by doses up to 18 g per day. [Paday-
atty et al, Ann Intern Med, 2004, 140, 533-7]. This discrepancy
has been explained in a recent book [Hickey and Roberts, Ascor-
bate, 2004, Lulu press].
The second error concerns the dose frequency. Since high doses
of vitamin C have a half-life of about 30 minutes, single or twice
daily doses do not increase plasma levels for more than a few hours
[Levine et al. JAMA 1999, 281,1415-23]. Such doses provide a
minimal protective effect. Given these infrequent doses, even a
small positive effect implies a powerful therapeutic potential.
Douglas and Hemila have not shown that vitamin C is ineffective
against the common cold, unless the doses used are both inade-
quate and inappropriate. They have, however, made clear that the
previous 65 years of research has been based on a range of doses
that are too small and too infrequent. Thus, the research to date
may grossly underestimate the
therapeutic value of vitamin C. Tests of appropriate dose levels
and timing regimes are urgently required.
Author’s reply
Hickey and Roberts claim that the prophylactic and therapeutic
trials that have been carried out to date have used a range of doses
that are too small and too infrequent. They speculate, on the basis
of pharmacodynamic studies, that prevention of disease would re-
quire a minimum of 2.5 g of vitamin C per day in divided doses.
If they firmly believe in their reasoning (there are good grounds
for debate), they or someone else need to undertake rigorous pro-
phylactic trials at such dosage levels.
Nevertheless, while stating that “prevention of disease requires a
minimum of 2.5 g/day”, Hickey and Roberts ignore our finding
that in six trials with participants under heavy physical or cold
stress or both, vitamin C halved the incidence of common cold
type of symptoms (our Fig 01). This benefit was seen with doses
of 0.25 to 1.0 g/day which is substantially less than those specu-
lated as minimal by Hickey and Roberts. Thus in our Fig 01 the
living conditions rather than the vitamin C dosage provided the
explanation to the heterogeneous trial results.
Our review does not claim that the issue is closed. It acknowledges
that vitamin C plays some biological role in defence against res-
piratory infections but finds no evidence that at doses up to 1 to
2 g/day vitamin C would prevent colds in the general population
or reduce common cold duration enough to justify regular sup-
plementation.
Finally, we drew attention to one study in which an 8 g therapeu-
tic dose seemed to be beneficial and underlined the fact that no
therapeutic trials have been carried out in children even though
the regular supplementation trials found greater effect in children.
Harri Hemilä and Robert M Douglas
Contributors
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T A B L E S
Characteristics of included studies
Study Anderson 1972
Methods Double blind RCT. Prophylaxis trial. Duration 3 months
Participants Canadian adults, both sexes. 407 vit C; 411 placebo. Recruitment specified previous cold proneness in the
winter months
Interventions 1 g/d vit C and 3 g/d extra for the first 3 days of illness
Outcomes Incidence (Comp 01) Duration (Comp 02) Severity (Comp 03)
Notes Jadad 5
PD = I
Allocation concealment A – Adequate
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Characteristics of included studies (Continued )
Study Anderson 1974a
Methods Double blind RCT. Duration 3 months. Four prophylaxis, two treatment and two placebo arms. This entry
reports a prophylaxis arm
Participants Canadian adults, both sexes. Data for this arm includes 277 vit C; 285 placebo
Interventions 1 g/d vit C and 4 g/d at onset of illness on the 1st day only
Outcomes Incidence (Comp 01) Duration (Comp 02) Severity (Comp 03)
Notes Jadad 5
PD = I
Problems with placebo group #6; see text
Allocation concealment A – Adequate
Study Anderson 1974b
Methods See Anderson 1974a
Prophylaxis arm
Participants 275 vit C
Interventions 1 g/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02) Severity (Comp 03)
Notes
Allocation concealment A – Adequate
Study Anderson 1974c
Methods See Anderson 1974a. Prophylaxis arm
Participants 308 vit C
Interventions 2 g/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02) Severity (Comp 03)
Notes
Allocation concealment A – Adequate
Study Anderson 1974d
Methods See Anderson 1974a. Prophylaxis arm
Participants 331 vit C
Interventions 0.25 g/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02) Severity (Comp 03)
Notes
Allocation concealment A – Adequate
Study Anderson 1974e
Methods See Anderson 1974a. Therapeutic arm
Participants 275 vit C
Interventions 4 g/d vit C on the 1st day of illness only
Outcomes Duration (Comp 04) Severity (Comp 05)
Notes
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Characteristics of included studies (Continued )
Allocation concealment A – Adequate
Study Anderson 1974f
Methods See for Anderson 1974a. Therapeutic arm
Participants 308 vit C
Interventions 8 g/d vit C on the 1st day of illness only
Outcomes Duration (Comp 04) Severity (Comp 05)
Notes
Allocation concealment A – Adequate
Study Anderson 1975a
Methods Double blind RCT. Therapeutic trial. Duration 15 weeks. Two active and one placebo arm. This arm used
vit C tablets
Participants Canadian adults, both sexes. 150 vit C; 146 placebo
Interventions 0.5 g weekly and 1.5 g/d on the 1st day of illness and 1 g/d for next 4 days
Outcomes Duration (Comp 04) Severity (Comp 05)
Notes Jadad 5
PD = I
Allocation concealment A – Adequate
Study Anderson 1975b
Methods See Anderson 1975a. This arm used vit C capsules
Participants 152 vit C
Interventions See Anderson 1975a
Outcomes Duration (Comp 04) Severity (Comp 05)
Notes
Allocation concealment A – Adequate
Study Audera 2001a
Methods Double-blind RCT. Therapeutic trial
Participants Australian adults of both sexes. 47 vit C; 42 placebo
Interventions 1 g/d vit C for 3 days. Placebo group received 30 mg/d vit C daily for 3 days
Outcomes Duration (Comp 04) Severity (Comp 05)
Notes Jadad 4
PD = I
Allocation concealment A – Adequate
Study Audera 2001b
Methods See Audera 2001a
Participants 50 vit C
Interventions 3 g/d vit C for 3 days
Outcomes Duration (Comp 04) Severity (Comp 05)
Notes
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Characteristics of included studies (Continued )
Allocation concealment A – Adequate
Study Audera 2001c
Methods See Audera 2001a
Participants 45 vit C
Interventions 3 g/d vit C for 3 days with flavonoids
Outcomes Duration (Comp 04) Severity (Comp 05)
Notes
Allocation concealment A – Adequate
Study Bancalari 1984
Methods Double-blind RCT. Prophylaxis trial. Duration 84 days
Participants Chilean school children, male and female, age 10 to 12 years. 32 vit C; 30 placebo
Interventions 2 g/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02)
Notes Jadad 3
PD = I
Allocation concealment B – Unclear
Study Briggs 1984
Methods Double blind RCT. Prophylaxis trial. Over 8 winters for 3 or 6 months of commitment by each volunteer
Participants Australian adults, male and female. 265 vit C; 263 placebo
Interventions 1 g/d vit C plus 4 g/d when respiratory symptoms occurred. Placebo group received 50 mg/d plus 200 mg/d
when ill
Outcomes Incidence (Comp 01) Duration (Comp 02)
Notes Jadad 3
PD = I
SD for duration was not published and it was estimated as SD = mean
Allocation concealment A – Adequate
Study Carr 1981a
Methods Double blind RCT. Prophylaxis trial. Identical twins: one group living together and the other living apart.
This deals with those living together. Duration 100 days
Participants Australian males and females age range 14 to 64 years (mean 25 years). 51 twin pairs living together
Interventions 1 g/d vit C. Both groups received a multi vitamin tablet that contained 70 mg/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02) Severity (Comp 03)
Notes Jadad 4
PD = I
SD for duration was not published and the SD was calculated from the P value
Allocation concealment A – Adequate
Study Carr 1981b
Methods See Carr 1981a. This deals with those living apart
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Characteristics of included studies (Continued )
Participants 44 twin pairs living apart
Interventions 1 g/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02) Severity (Comp 03)
Notes Jadad 4
PD = I
Allocation concealment A – Adequate
Study Carson 1975
Methods Double blind RCT. Prophylaxis trial. Duration 40 days
Participants UK adults. 121 vit C; 123 placebo
Interventions 1 g/d vit C
Outcomes Incidence (Comp 01)
Notes Jadad 3
PD = ?
Allocation concealment C – Inadequate
Study Charleston 1972
Methods Single blind not randomised. Prophylaxis trial. Duration 15 weeks
Participants Staff and students of the University of Strathclyde UK. 47 vit C; 43 placebo
Interventions 1 g/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02)
Notes Jadad 0
PD = ?
Allocation concealment C – Inadequate
Study Clegg 1975
Methods Double blind RCT. Prophylaxis trial. Duration 15 weeks
Participants Scottish students. 67 vit C; 70 placebo
Interventions 1 g/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02)
Notes Jadad 2
PD = I
Allocation concealment B – Unclear
Study Coulehan 1974a
Methods Double blind, alternate allocation. Prophylaxis trial. Duration 14 weeks
Participants USA. Students at a Navajo Indian school. Older residential students. 131 vit C; 128 placebo
Interventions 2 g/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02)
Notes Jadad 4
PD = I
SD for duration was not published and it was estimated as SD = mean
Allocation concealment C – Inadequate
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Characteristics of included studies (Continued )
Study Coulehan 1974b
Methods See Coulehan 1974a
Participants Younger residential students. 190 vit C; 192 placebo
Interventions 1 g/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02)
Notes
Allocation concealment C – Inadequate
Study Coulehan 1976
Methods Double blind RCT. Prophylaxis trial. Duration 18 weeks in one school and 15 weeks in another
Participants USA. Children at two Navajo Indian residential schools, age 6 to 15 years. Both sexes. 428 vit C; 428 placebo
Interventions 1 g/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02)
Notes Jadad 4
PD = I
SD for duration was not published and it was estimated as SD = mean
Allocation concealment A – Adequate
Study Cowan 1942
Methods Placebo-controlled, allocation method not evident. Prophylaxis trial
Participants US College students. 208 vit C; 155 placebo
Interventions 0.2 g/d vit C
Outcomes Incidence (Comp 01)
Notes Jadad 2
PD = ?
SD for duration was not published and it was estimated as SD = mean
Allocation concealment B – Unclear
Study Cowan 1950
Methods Probably double blind RCT. Therapeutic trial
Participants US College students. 76 vit C; 77 placebo
Interventions 0.67 g of vit C for every 4 hours, with a maximum of 10 doses (total 6.7 grams); i.e. about 3 g/d for 2 days
Outcomes Duration (Comp 04)
Notes Jadad 3
PD = ?
Allocation concealment B – Unclear
Study Dahlberg 1944
Methods Double-blind RCT. Prophylaxis trial. Duration 57 days
Participants Swedish army. 1259 vit C; 1266 placebo
Interventions 0.2 g/d vit C during the first 24 days; 50 mg/d thereafter
Outcomes Incidence (Comp 01)
Notes Jadad 3
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Characteristics of included studies (Continued )
PD = ?
Allocation concealment B – Unclear
Study Dick 1990
Methods Brief abstract report of three experimental prophylaxis studies using intense exposure to infected volunteers
Participants USA, adult volunteers. 24 vit C; 24 placebo
Interventions 2 g/d vit C
Outcomes Shown in Table 1. Not included in meta-analyses
Notes Jadad 2
PD = ?
Three abstracts, no full paper
Allocation concealment B – Unclear
Study Elwood 1976
Methods Double-blind RCT. Prophylaxis trial
Participants Wales, young mothers. 339 vit C; 349 placebo
Interventions 1 g/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02)
Notes Jadad 2
PD = ?
Allocation concealment B – Unclear
Study Elwood 1977
Methods Double-blind RCT. Therapeutic trial
Participants Wales, young mothers. 145 colds treated with vit C and 119 treated with placebo
Interventions 4 g/d vit C daily for the first 2.5 days of illness
Outcomes Duration (Comp 02)
Colds were classified either as simple or chest colds
Notes Jadad 2
PD = ?
If the chest colds lasting more than 20 days are included in the comparison the statistically significant
difference favouring vit C disappears
Allocation concealment B – Unclear
Study Franz 1956
Methods Single blind. Prophylaxis study. 2 x 2 factorial: vit C and flavonoids
Participants German medical students and nurses. 44 vit C; 45 no-vit C
Interventions 0.2 g/d vit C
Outcomes Incidence (Comp 01)
Notes Jadad 4
PD = ?
In vitamin C group 93%(13/14) of colds were cured or improved in 5 days versus 53% (8/15) in the placebo
group (P = 0.024; Hemilä 2006a)
Allocation concealment A – Adequate
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Characteristics of included studies (Continued )
Study Himmelstein 1998a
Methods Double blind RCT. Prophylaxis trial. Duration 2 months before and 1 month after marathon race
Participants USA. Marathon runners. 30 vit C; 14 placebo
Interventions 1 g/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02) Severity (Comp 03)
Notes Jadad 3
PD = I
High and statistically significant differential dropout of placebo recipients; see text
Allocation concealment A – Adequate
Study Himmelstein 1998b
Methods See Himmelstein 1998a. Sedentary controls for the marathon runners
Participants US sedentary people. 23 vit C; 25 placebo
Interventions 1 g/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02) Severity (Comp 03)
Notes
Allocation concealment A – Adequate
Study Karlowski 1975a
Methods Double blind RCT. 2 x 2 factorial: prophylaxis and therapeutic vitamin C.Duration 9months.We compared
3 different arms with the placebo arm. This is prophylaxis arm
Participants USA, employees of the NIH. 44 vit C; 46 placebo
Interventions 3 g/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02)
Notes Jadad 4
PD = ?
The authors believed that the benefits observed were attributable to the breaking of the patient blind but see
Hemilä 1996a, 2006a
Allocation concealment B – Unclear
Study Karlowski 1975b
Methods See Karlowski 1975a. This is prophylaxis plus therapeutic arm
Participants 57 vit C
Interventions 3 g/d vit C and 3 g/d therapeutic from the onset of cold for 5 days
Outcomes Incidence (Comp 01) Duration (Comp 02)
Notes
Allocation concealment B – Unclear
Study Karlowski 1975c
Methods See Karlowski 1975a. This is therapeutic only arm
Participants 43 vit C
Interventions 3 g/d therapeutic vit C from the onset of cold for 5 days
Outcomes Duration (Comp 04)
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Characteristics of included studies (Continued )
Notes
Allocation concealment B – Unclear
Study Liljefors 1972
Methods Double blind RCT. Crossover prophylaxis trial. Duration 2 + 2 weeks. In the first 2 weeks 25 participants
received vit C and 18 placebo. As participants became ill they were removed from the trial and 3 persons
withdrew. In the second period, 18 received placebo and 8 vitamin C
Participants Swedish army males. 33 vit C; 33 placebo
Interventions 2 g/d vit C for two weeks
Outcomes Incidence (Comp 01)
Notes Jadad 3
PD = ?
Allocation concealment A – Adequate
Study Ludvigsson 1977a
Methods Double blind RCT. Prophylaxis trial. Duration 7 weeks
Participants Swedish school children. 80 vit C; 78 placebo
Interventions 1 g/d vit C. Placebo contained 30 mg/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02) Severity (Comp 03)
Notes Jadad 3
PD = I
Pilot study to Ludviggson 1977b
Allocation concealment B – Unclear
Study Ludvigsson 1977b
Methods Double blind RCT. Prophylaxis trial. Duration 3 months
Participants Swedish school children. 304 vit C; 311 placebo
Interventions 1 g/d vit C. Placebo contained 10 mg/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02) Severity (Comp 03)
Notes Jadad 3
PD = I
Allocation concealment B – Unclear
Study Miller 1977a
Methods Double blind RCT. Prophylaxis trial. Identical twins
Participants US school children. 12 twin pairs “high body weight”
Interventions 1 g/d vit C. Placebo contained 50 mg/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02) Severity (Comp 03)
Notes Jadad 4
PD = I
Allocation concealment B – Unclear
Study Miller 1977b
Methods See Miller 1977a
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Characteristics of included studies (Continued )
Participants 12 twin pairs “medium body weight”
Interventions 0.75 g/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02) Severity (Comp 03)
Notes Jadad 4
PD = I
Allocation concealment B – Unclear
Study Miller 1977c
Methods See Miller 1977a
Participants 20 twin pairs “low body weight”
Interventions 0.5 g/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02) Severity (Comp 03)
Notes Jadad 4
PD = I
Allocation concealment B – Unclear
Study Moolla 1996a
Methods Double blind RCT. Prophylaxis trial. Ultra marathon runners. Duration 6 weeks before and 2 weeks after
the race
Participants South Africa. Ultramarathon runners. 13 vit C; 19 placebo
Interventions 0.25 g/d vit C
Outcomes Incidence (Comp 01)
Notes Jadad =3
PD = ?
1/4 of those who reported respiratory symptoms in vit C group and 8/13 in placebo group reported that
their respiratory symptoms were severe (P = 0.08)
Allocation concealment B – Unclear
Study Moolla 1996b
Methods See Moolla 1996a
Participants Sedentary controls for runners. 11 vit C; 19 placebo
Interventions 0.25 g/d vit C
Outcomes Incidence (Comp 01)
Notes 0/6 of those who reported respiratory symptoms in vit C group and 4/7 in placebo group reported that their
respiratory symptoms were severe (P = 0.02)
Allocation concealment B – Unclear
Study Peters 1993a
Methods Double blind RCT. Prophylaxis trial. Ultramarathon runners. Duration 3 weeks before and 2 weeks after
the race
Participants South Africa. Ultramarathon runners. 43 vit C; 41 placebo
Interventions 0.6 g/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02)
Notes Jadad 2
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Characteristics of included studies (Continued )
PD = I
Allocation concealment C – Inadequate
Study Peters 1993b
Methods See Peters 1993a. Sedentary controls for the runners
Participants Sedentary controls. 34 vit C; 39 placebo
Interventions 0.6 g/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02)
Notes
Allocation concealment C – Inadequate
Study Peters 1996a
Methods Double blind RCT. Prophylaxis trial. Ultramarathon runners. Duration 21 days prior to the race
Participants South Africa. Ultramarathon runners. 44 vit C; 47 placebo
Interventions 0.5 g/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02)
Notes Jadad 3
PD = ?
SD for duration was not published and it was estimated as SD = mean
Allocation concealment B – Unclear
Study Peters 1996b
Methods See Peters 1966a. Family controls of runners
Participants South Africa. Family controls for runners. 41 vit C; 45 placebo
Interventions 0.5 g/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02)
Notes
Allocation concealment B – Unclear
Study Pitt 1979
Methods Double blind RCT. Prophylaxis trial. Duration 8 weeks
Participants USA Marine recruits. 331 vit C; 343 placebo
Interventions 2 g/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02) Severity (Comp 03)
Notes Jadad 5
PD = I
SD for duration was not published and it was estimated as SD = mean
Allocation concealment A – Adequate
Study Ritzel 1961
Methods Double blind RCT. Prophylaxis trial. Duration 2 weeks
Participants Children attending ski school in Swiss Alps. 139 vit C; 140 placebo
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Characteristics of included studies (Continued )
Interventions 1 g/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02)
Notes Jadad 3
PD = I
SD for duration was not published and the SD was calculated from the P value
Allocation concealment A – Adequate
Study Sabiston 1974
Methods Double blind RCT. Prophylaxis trial. Duration about 2 to 3 weeks
Participants Canadian male military recruits during subarctic winter exercises. 56 vit C; 56 placebo
Interventions 1 g/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02)
Notes Jadad 1
PD = I
Allocation concealment C – Inadequate
Study Sasazuki 2006
Methods Double blind RCT. Prophylaxis trial. Duration 3.5 years
Participants Japanese males and females, mean age 57 years. 140 vit C; 133 placebo
Interventions 0.5 g/d vit C. Placebo contained 50 mg/d vit C
Outcomes Incidence (Comp 01)
ITT results are shown
Notes Jadad 5
PD = ?
Additional data provided by authors.
Duration and severity of colds were reported, but they were recorded on the period after supplementation
had been stopped, with no rationale described for such a comparison
Allocation concealment A – Adequate
Study Schwartz 1973
Methods Double blind experimental prophylaxis study with nasal instillation of virus after 2 weeks of pre-treatment
Participants Male US prison volunteers. 11 vit C; 10 placebo
Interventions 3 g/d vit C
Outcomes Shown in Table 1
Not included in meta-analyses
Notes Jadad 2
PD = ?
Allocation concealment C – Inadequate
Study Tyrrell 1977
Methods Double blind RCT. Therapeutic trial
Participants UK, both sexes. 274 episodes treated with vit C; 329 placebo
Interventions 4 g/d vit C for the first 2.5 days of illness
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Characteristics of included studies (Continued )
Outcomes Duration (Comp 04) Severity (Comp 05)
Notes Jadad 4
PD = I
Allocation concealment B – Unclear
Study Van Straten 2002
Methods Double-blind RCT. Prophylaxis trial. Duration 60 days
Participants UK, both sexes. 84 vit C; 84 placebo
Interventions 1 g/d vit C. Esther-C ascorbate, a form that, according to authors, “allows cells to efficiently absorb and
retain high levels of vitamin”
Outcomes Incidence (Comp 01) Duration (Comp 02)
Notes Jadad 4
PD = ?
Allocation concealment A – Adequate
Study Walker 1967
Methods Experimental prophylaxis study in which healthy volunteers were intranasally inoculated with viruses. Du-
ration 3 days before and 6 days after nasal instillation of virus
Participants UK adults both sexes. 47 vit C; 44 placebo
Interventions 3 g/d vit C
Outcomes Shown in Table 1
Not included in meta-analyses
Notes Jadad 0
PD = I
Allocation concealment C – Inadequate
Study Wilson 1973a
Methods Double blind RCT. Prophylaxis trial. Duration 9 months
Participants UK boarding school girls. 70 vit C; 58 placebo
Interventions 0.2 g/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02) Severity (Comp 03)
Notes Jadad 4
PD = ?
Complicated classification system makes comparison with other trials difficult
Allocation concealment A – Adequate
Study Wilson 1973b
Methods See Wilson 1973a
Participants UK boarding school boys. 88 vit C; 86 placebo
Interventions 0.2 g/d vit C
Outcomes Incidence (Comp 01) Duration (Comp 02) Severity (Comp 03)
Notes
Allocation concealment A – Adequate
g/d: grams per day
33Vitamin C for preventing and treating the common cold (Review)
Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
mg/d: milligrams per day
PD: placebo distinguishability
SD: standard deviation
ITT: intention to treat
NIH: National Institutes for Health
Characteristics of excluded studies
Study Reason for exclusion
Abbott 1968 Data not suitable for inclusion in our meta-analyses. This randomized placebo-controlled therapeutic trial
involved 270 family members of 78 UK general practitioners. Males and females were in equal numbers; 39%
were 20 years or younger, 52% were from 21 to 50 years. 3 g/d vitamin C was used to treat 147 patients
“continued as long as necessary, up to a total of fourteen days” and 133 received placebo. Clinical scores for
a range of symptoms were computed and stated not to be different between the two groups: “with regard to
the comparative results with the two preparations, there were virtually no differences at all in respect of any of
these individual symptoms” (p. 444). However, the only available data reports the severity of “sore throat in
patients with a common cold” (Table 1 on p. 443). Thus no usable data could be extracted from the paper to
our meta-analyses. It is not clear how long a delay there was between the onset of symptoms and the initiation
of treatment. “The doctors taking part in the trial were asked to treat families in order, as colds appeared during
the course of the winter” (p. 442), thus it seems that the doctor gave tablets only when he or she met the patient
rather than patient keeping tablets ready at home for use when symptoms started
Asfora 1977 No placebo comparison. A Brazilian study involving males and females aged between 14 and 89. The author
describes: “a double-blind trial was conducted in which the preparations, numbered 1 and 8, were given to
alternate patients as they presented themselves. .. 2 g three times per day for five consecutive days, or in other
words 6 g per day or a total of 30 g. When 42 patients had received substance No. 1 and 41 patients had
received No. 8, there was no longer any point in continuing the double-blind trial, since in view of the clinical
progress of the patients there was not the slightest doubt that substance No. 1 was vitamin C and No. 8 was the
placebo” (p. 224). Thereafter the trial was continued as an open trial comparing vitamin C with other drugs.
Rapid initiation of vitamin C supplementation (< 24 hours from the onset of symptoms) appeared beneficial,
whereas late initiation (> 24 hours) did not. The paper suggests a bias of the investigator towards the therapeutic
benefits of vitamin C
Baird 1979 Low dose. 362 UK students aged 17 to 25 years were studied for 72 days in a double-blind RCT of prophylaxis.
A daily drink contained either synthetic orange juice without ascorbic acid, synthetic juice with 0.08 g/d of
ascorbic acid added, or natural orange juice with 0.08 g/d of ascorbic acid added. There was a highly significant
reduction in common cold incidence among males (RR = 0.63; 95% CI: 0.50 to 0.78) but not in females (RR
= 1.24; 0.95 to 1.61) (Hemilä 1997a, Hemilä 2006a)
Barnes 1961 No placebo comparison. A trial in the USA. A multivitamin preparation that included 0.2 g/d vitamin C was
given to 23 members (10 boys, 13 girls) of a basketball team for 7 weeks; medication being received from
the coaches. The cold outcomes were compared with those of 16 people (8 boys, 8 girls) of the same age and
background. The controls reported to the coaches daily. Days sick from cold were counted in each group. The
study took place over 8 weeks during which the basketball players took medication on an average of 43 days.
The only usable outcome was “mean days per person” in the vitamin C group 1.48 (SD 2.65) and in the control
group 6.87 (SD 8.57) . However, there are serious doubts about the comparability of the controls who were
apparently not basketball players
Bartley 1953 Low dose. “The volunteers did not know to which group they belonged, nor did the physicians responsible for
the clinical investigations. All the volunteers were given each day 7 supplementary tablets of identical taste and
appearance, some containing vitamin C, others being dummies” (p.8). Three participants were administered
0.07 g/d vitamin C and a total of 14 cold episodes were recorded among them in the follow up, four participants
were administered 0.01 g/d vitamin C (18 colds), and six persons were administered no vitamin C (30 colds).
The geometric mean length of colds in vitamin C deprived subjects was 6.4 days, and in non-deprived subjects
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3.3 days, and the authors concluded “such evidence as there is definitely confirms the hypothesis that the absence
of vitamin C tended to cause colds to last longer” (p. 43)
Bendel 1955 No placebo comparison and the control group was not parallel. 120 children at a summer camp for two weeks
were given 0.2 g/d vitamin C daily and their cold experience was compared with that of participants in an earlier
camp
Bergquist 1943 Low dose. A Swedish trial involving supplementation with only 0.03 g/d vitamin C
Bessel-Lorck 1958 No placebo comparison. Berlin school children in a skiing camp. Abridged summary: “26 subjects received 1
g of vitamin C daily during the first 9 days. Under this regimen only one student became sick. In 20 subjects
the prophylaxis did not begin until the 9th day. At this point in time 9 students were already sick with upper
respiratory infections; and 3 others became infected within the first 3 days after the trial began. All of those who
were sick were treated with 2 g of vitamin C per day. Within just 24 hours a rapid improvement in the general
condition was evident so that elevated physical demands were met without particular difficulty. All subjects
displayed a significant increase in their capacity to perform physical activities while being treated with vitamin
C.” The Bessel-Lorck paper is available as a translation. This trial motivated Ritzel (1961) to carry out his trial
Boines 1956 No placebo comparison. Study of poliomyelitis sufferers
Brown 1945 No data that could be used in our meta-analyses. RCT comparison of US college students. Outcome was “Colds
that did not develop” and benefit was claimed
Chavance 1993 Low dose. Double blind RCT of 0.09 g/d vitamin C in elderly participants. No benefit was demonstrated
Cuendet 1946 No placebo comparison. 200 children in three mountain parishes took vitamin C supplements up to 0.3 g/d
Dyllick 1967 Noplacebo comparison.Cohortworkplace study involving 200 recipients of 1g/d of vitaminCwhose respiratory
experience was compared with those not receiving vitamin C
Elliot 1973 Data not suitable for inclusion in our meta-analyses. Authors describe: “A double blind study was initiated on
a Polaris submarine...0.5 g of ascorbic acid or a citric acid placebo would be taken four times a day. Seventy of a
140 man crew volunteered and were randomly placed in treatment or placebo groups... Both ascorbic acid and
placebo capsules looked identical and when opened the contents were similar in taste and appearance... at the
end of the tenth week the study was terminated” (p. 12). “There was no consistent difference between groups
in the incidence of runny nose or sneezing. Man-days of morbidity for hoarseness, sore throats, non-productive
coughs, and productive coughs was 36, 107, 42 and 72 in the placebo group with only 37%, 28%, 40% and
31% as much morbidity in the ascorbic acid group. The Wilcoxon Sequence Test with a one tailed test rejected
the null hypothesis of equal effectiveness of ascorbic acid and placebo for sore throats and productive coughs
(P = .0155 and .0327) but not for hoarseness or non-productive coughs” (p. 12) (see Hemilä 2004a)
Fogelholm 1998 Vitamin C in combination with other antioxidants. Finnish study involving 75 athletes. RCT of 1 g/d vitamin
C with 0.3 g/d vitamin E and 0.09 g/d ubiquinone vs. an undescribed placebo. Methodologically strong study
but was excluded from the meta-analyses because there were three antioxidants in the active preparation which
were each hypothesized to be potentially beneficial
Glazebrook 1942 Low dose. 1500 boys of a UK boarding school during the World War II. The participants were allocated as
administrative units and not on individual basis. Vitamin C (0.05 to 0.3 g/d) was added to cocoa andmilk in the
kitchen to a group of 335 boys. Although ineffective powder was not added to the drinks of the control group,
it may be assumed that the control drinks served functionally as a placebo. Colds were slightly less frequent in
the vitamin C group (RR = 0.83; 95% CI: 0.64 to 1.07) (Hemilä 1997a; Hemilä 2004a)
Gormly 1977 No placebo comparison. Fourteen males of 29 members of a one year Antarctic expedition took 1 g/d vitamin
C throughout their stay. Their health outcomes were compared with the remaining group who did not to take
vitamin C, and no difference was observed between the two groups
Gorton 1999 No placebo comparison and the control group not parallel. A technical training facility in Chile was the site of
this cohort study in which the experience of 250 trainees who were given 3 g/d vitamin C during their 10 day
course. Vitamin C group was compared with a control group of 463 students who had been monitored in a
somewhat similar way during the previous year (sic!)
Hopfengärtner 1944 Low dose. Long term hospital baby study in which supplementation of 0.05 g/d vitamin C was used
35Vitamin C for preventing and treating the common cold (Review)
Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Characteristics of excluded studies (Continued )
Hunt 1994 Not focused on the common cold. Double blind RCT. 57 elderly UK patients suffering from acute bronchitis
or pneumonia who were admitted to hospital for treatment were administered 0.2 g/d of vitamin C (Hemilä
2007)
Kimbarowski 1967 No placebo comparison, no data suitable for inclusion in our meta-analyses. 216 Russian soldiers were hospi-
talized because of influenza A. 114 were administered 0.2 g/d vitamin C. There were 2 cases of pneumonia in
the vitamin C group in comparison with 10 cases in the control group. Thus the trial found a lower incidence
of complications of viral respiratory infection (Hemilä 2004a, Hemilä 2007)
Koytchev 2003 No placebo comparison. Double blind RCT involving 1167 participants. Four arms, colds treated with 0.9 g/d
vitamin C plus or minus antihistamine and antipyretics
Masek 1974 Low dose. Two large studies of Czeck coal miners comparing 0.1 g/d vitamin C and placebo over a period of 4
or 8 weeks. Excluded both on the basis of low dose and inadequacy of data for inclusion in meta-analyses. The
trials were neither randomised nor blind. Authors claimed benefits to the active recipients
Niemi 1951 Low dose and no placebo comparison. Finnish study with military recruits. 1036 people were observed during
a 3 month period. 516 were administered 0.1 g/d vitamin C. No benefits claimed
Peters 1940 No placebo comparison. Short term baby supplementation study
Regnier 1968 No suitable data. The author describes: “I initiated a double-blind study using ascorbic acid alone, ascorbic
acid plus bioflavonoids, flavonoids only and, fourthly, a lactose placebo with the two ’vitamins’ present either
alone or together in 0.2 g quantities. It was shortly obvious that there was no need to continue double-blind
techniques. The continued studies were done by the single blind method... I limited myself to 22 subjects...
The majority were adults whose ages ranged from 30 to 50, with the extremes being five children younger than
12 (p. 949).” “The 22 subjects mentioned have been studied systematically and under conditions which were
as controlled as is possible in a clinical investigation of an infection such as the common cold. Some acted as
what are commonly termed their own controls... None of the subjects was studied for less than three years... (p.
950).” “Within the first 24 hours of a typical infection which the patient recognizes as his usual early symptoms
of a cold, and the sooner the better, the beginning dose of ascorbic acid or 0.6 or 0.625 g is taken every three
hours” (p. 950). The author reports that “in 50 colds the treatment consisted of ascorbic acid alone ... the colds
were nicely suppressed in 45 [of the 50]... In 22 of 24 instances in which the lactose-filled capsules alone were
taken the colds were seemingly untempered and ordinary” (p. 952). The placebo-controlled observations thus
suggest benefit, but there are no data suitable for inclusion in our meta-analyses
Scheunert 1949 Data not suitable for inclusion in our meta-analyses. Large study involving factory workers in Germany between
November 1942 in June 1943. Pills were distributed by foremen and managers. Different doses of vitamin C
were administered to four study groups (range 0.02 to 0.3 g/d) so that the lowest dose arm(s) might be used as
the control group. The common cold [Erkältungskrankheiten] was one of the outcomes and “The percentual
monthly duration of people sick with the common cold [Prozentualer Monatsdurchschnitt der erkrankten
Personen]” was 7.3% in the 0.02 g/d group, 7.2% in the 0.05 g/d group, 1.95% in the 0.1 g/d group, and
1.93% in the 0.3 g/d group suggesting that there were more days sick with the common cold when vitamin C
doses were low. However, the data are presented ambiguously and it is a combination of incidence and duration,
and no data could be extracted to our meta-analyses
Tebrock 1956 Data not suitable for inclusion in our meta-analyses. 2000 adult subjects presenting with colds to industrial
clinics were sequentially assigned to receive 0.2 g/d vitamin C and flavonoids in a 2 x 2 factorial design. All
cases were again examined 3 days later by one of three physicians. The authors’ conclusion from the extensively
detailed tabulations is that “the overwhelming impression gained from the study is the singular lack of effect in
altering the course of the common cold by either the bioflavonoids or the ascorbic acid”. Recorded outcomes
could not be used in this overview
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A D D I T I O N A L T A B L E S
Table 01. Three volunteer transmission studies
Study Characteristic Walker 1967 Schwartz 1973 Dick 1990
Number of participants 91 healthy volunteers; 47 vitamin
C and 44 placebo
21 healthy male volunteers Altogether 48 participants.
Three separate transmission
experiments each involving 16
healthy volunteers (8 vitamin C;
8 placebo) housed closely for one
week with 8 volunteers actively
infected with rhinovirus
Viruses used Rhinovirus (3 strains); 29 vitamin
C and 26 placebo
Influenza B (8 / 8)
B814 virus (10 / 10)
Rhinovirus 44 ; 11 vitamin C and
10 placebo
Rhinovirus 16 ; 24 vitamin C and
24 placebo
Transmission method Nasal instillation Nasal instillation Close contact with infected
volunteers over a period of a week
Intervention 1 g/d vitamin C for 3 days before
and 6 days after inoculation
3 g/d vit C or placebo for 2
weeks before and 1 week after
inoculation
2 g/d vitamin C for 3.5 weeks
before exposure to infected
volunteers
Incidence outcome 18 colds developed in each group All in both groups developed
colds
19/24 in vitamin C group and
22/24 in placebo group became
infected
Duration outcome Mean duration in each group 5
days
Both groups resolved by 6 to 7
days
Not provided
Severity outcome Mean severity score 8 for vitamin
C and 7 for placebo
Severity peaked earlier for vitamin
C group and resolution more
advanced by day 4 (P = 0.02).
Overall mean severity scores not
significantly different in the two
groups
Mean cumulative severity score
and mucous weights reduced in
the vit C recipients (P = 0.03).
Severity of colds reduced by 50%
(P = 0.02; Mink 1988)
Comments Not double blind Double blind. Nasal virus
shedding similar in the two
groups
Double blind. Virus shedding
similar in these two groups . The
studies are briefly described in
a series of conference abstracts
but no full published paper is
available
A N A L Y S E S
Comparison 01. Development of colds while on vitamin C prophylaxis
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Proportions developing one
or more cold episodes during
prophylaxis
30 11350 Relative Risk (Random) 95% CI 0.96 [0.92, 1.00]
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Comparison 02. Duration of colds developing on vitamin C prophylaxis
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Duration of common cold
symptoms (placebo group
duration set as 100%)
30 9676 Weighted Mean Difference (Random) 95% CI -9.73 [-14.07, -5.39]
Comparison 03. Severity of colds developing on vitamin C prophylaxis
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Indicators of severity of
episodes experienced while on
prophylaxis
15 7045 Standardised Mean Difference (Random) 95%
CI
-0.13 [-0.21, -0.04]
Comparison 04. Duration of colds treated with vitamin C
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Mean symptom days per
episode standardised against
control group
7 3294 Weighted Mean Difference (Random) 95% CI -2.54 [-10.09, 5.02]
Comparison 05. Severity of colds treated with vitamin C
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Indicators of severity of
episodes for which vit C was
used as therapy
4 2753 Standardised Mean Difference (Random) 95%
CI
-0.07 [-0.16, 0.02]
I N D E X T E R M S
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Analysis 01.01. Comparison 01 Development of colds while on vitamin C prophylaxis, Outcome 01
Proportions developing one or more cold episodes during prophylaxis
Review: Vitamin C for preventing and treating the common cold
Comparison: 01 Development of colds while on vitamin C prophylaxis
Outcome: 01 Proportions developing one or more cold episodes during prophylaxis
Study Vitamin C Placebo Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 All eligible trials with exception of subgroup removed below
Anderson 1972 302/407 335/411 10.6 0.91 [ 0.85, 0.98 ]
Anderson 1974a 922/1191 233/285 11.6 0.95 [ 0.89, 1.01 ]
Bancalari 1984 21/32 21/30 1.4 0.94 [ 0.67, 1.32 ]
Briggs 1984 125/265 121/263 4.0 1.03 [ 0.85, 1.23 ]
Carson 1975 85/121 84/123 4.5 1.03 [ 0.87, 1.22 ]
Charleston 1972 31/47 37/43 2.6 0.77 [ 0.60, 0.97 ]
Clegg 1975 48/67 50/70 3.2 1.00 [ 0.81, 1.24 ]
Coulehan 1974a 19/190 23/192 0.5 0.83 [ 0.47, 1.48 ]
Coulehan 1974b 16/131 17/128 0.4 0.92 [ 0.49, 1.74 ]
Coulehan 1976 98/428 98/428 2.5 1.00 [ 0.78, 1.28 ]
Cowan 1942 184/208 142/155 11.1 0.97 [ 0.90, 1.03 ]
Dahlberg 1944 131/1259 142/1266 2.9 0.93 [ 0.74, 1.16 ]
Elwood 1976 296/339 298/349 11.9 1.02 [ 0.96, 1.09 ]
Franz 1956 14/44 15/45 0.5 0.95 [ 0.52, 1.74 ]
Himmelstein 1998b 10/23 8/25 0.3 1.36 [ 0.65, 2.84 ]
Liljefors 1972 10/33 9/33 0.3 1.11 [ 0.52, 2.38 ]
Ludvigsson 1977a 49/80 44/78 2.2 1.09 [ 0.84, 1.41 ]
Ludvigsson 1977b 230/304 240/311 9.3 0.98 [ 0.90, 1.07 ]
Moolla 1996b 5/11 12/19 0.3 0.72 [ 0.35, 1.50 ]
Peters 1993b 18/34 18/39 0.8 1.15 [ 0.72, 1.82 ]
Peters 1996b 5/41 11/45 0.2 0.50 [ 0.19, 1.31 ]
Pitt 1979 298/331 309/343 12.8 1.00 [ 0.95, 1.05 ]
Sasazuki 2006 68/140 67/133 2.6 0.96 [ 0.76, 1.23 ]
Van Straten 2002 35/84 34/84 1.2 1.03 [ 0.72, 1.48 ]
Subtotal (95% CI) 5810 4898 97.7 0.98 [ 0.95, 1.00 ]
Total events: 3020 (Vitamin C), 2368 (Placebo)
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Study Vitamin C Placebo Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Test for heterogeneity chi-square=17.75 df=23 p=0.77 I² =0.0%
Test for overall effect z=1.92 p=0.05
02 Short term exposure to cold and/or severe physical stress
Himmelstein 1998a 10/30 6/14 0.3 0.78 [ 0.35, 1.71 ]
Moolla 1996a 4/13 13/19 0.2 0.45 [ 0.19, 1.07 ]
Peters 1993a 14/43 28/41 0.7 0.48 [ 0.30, 0.77 ]
Peters 1996a 7/44 19/47 0.3 0.39 [ 0.18, 0.84 ]
Ritzel 1961 17/139 31/140 0.6 0.55 [ 0.32, 0.95 ]
Sabiston 1974 6/56 14/56 0.2 0.43 [ 0.18, 1.04 ]
Subtotal (95% CI) 325 317 2.3 0.50 [ 0.38, 0.66 ]
Total events: 58 (Vitamin C), 111 (Placebo)
Test for heterogeneity chi-square=1.93 df=5 p=0.86 I² =0.0%
Test for overall effect z=4.98 p<0.00001
Total (95% CI) 6135 5215 100.0 0.96 [ 0.92, 1.00 ]
Total events: 3078 (Vitamin C), 2479 (Placebo)
Test for heterogeneity chi-square=45.26 df=29 p=0.03 I² =35.9%
Test for overall effect z=2.02 p=0.04
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Analysis 02.01. Comparison 02 Duration of colds developing on vitamin C prophylaxis, Outcome 01 Duration
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Review: Vitamin C for preventing and treating the common cold
Comparison: 02 Duration of colds developing on vitamin C prophylaxis
Outcome: 01 Duration of common cold symptoms (placebo group duration set as 100%)
Study Vitamin C Placebo Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Prophylaxis 200 mg or more daily plus or minus loading dose at cold onset in adults
Anderson 1972 561 95.00 (92.00) 609 100.00 (82.00) 9.3 -5.00 [ -15.02, 5.02 ]
Anderson 1974a 1823 93.00 (102.00) 437 100.00 (99.00) 8.9 -7.00 [ -17.40, 3.40 ]
Briggs 1984 125 94.00 (94.00) 121 100.00 (100.00) 2.7 -6.00 [ -30.27, 18.27 ]
Carr 1981a 94 101.00 (96.00) 70 100.00 (96.00) 1.9 1.00 [ -28.70, 30.70 ]
Carr 1981b 57 65.00 (75.00) 71 100.00 (75.00) 2.4 -35.00 [ -61.14, -8.86 ]
Charleston 1972 44 84.00 (46.00) 80 100.00 (20.00) 6.1 -16.00 [ -30.28, -1.72 ]
Clegg 1975 68 95.00 (41.00) 73 100.00 (39.00) 6.8 -5.00 [ -18.23, 8.23 ]
Elwood 1976 627 94.00 (90.00) 690 100.00 (99.00) 9.1 -6.00 [ -16.21, 4.21 ]
Himmelstein 1998a 15 200.00 (129.00) 12 100.00 (77.00) 0.3 100.00 [ 21.52, 178.48 ]
Himmelstein 1998b 14 60.00 (26.00) 12 100.00 (82.00) 0.8 -40.00 [ -88.35, 8.35 ]
Karlowski 1975a 128 87.40 (51.50) 65 100.00 (52.00) 5.5 -12.60 [ -28.07, 2.87 ]
Peters 1993a 14 103.00 (17.00) 28 100.00 (42.00) 4.4 3.00 [ -14.93, 20.93 ]
Peters 1993b 18 75.00 (38.00) 18 100.00 (56.00) 1.7 -25.00 [ -56.26, 6.26 ]
Peters 1996a 7 85.00 (85.00) 19 100.00 (100.00) 0.3 -15.00 [ -92.37, 62.37 ]
Peters 1996b 5 136.00 (136.00) 11 100.00 (100.00) 0.1 36.00 [ -97.05, 169.05 ]
Pitt 1979 600 97.40 (100.00) 619 100.00 (100.00) 8.2 -2.60 [ -13.83, 8.63 ]
Sabiston 1974 6 72.00 (50.00) 14 100.00 (50.00) 0.8 -28.00 [ -75.82, 19.82 ]
Van Straten 2002 37 58.00 (96.00) 50 100.00 (150.00) 0.7 -42.00 [ -93.82, 9.82 ]
Subtotal (95% CI) 4243 2999 70.2 -8.02 [ -13.08, -2.96 ]
Test for heterogeneity chi-square=21.88 df=17 p=0.19 I² =22.3%
Test for overall effect z=3.11 p=0.002
02 Prophylaxis 200 mg or more daily plus or minus loading dose at cold onset in children
Bancalari 1984 38 76.00 (62.00) 46 100.00 (65.00) 2.2 -24.00 [ -51.23, 3.23 ]
Coulehan 1974a 19 88.00 (88.00) 23 100.00 (100.00) 0.6 -12.00 [ -68.88, 44.88 ]
Coulehan 1974b 16 71.00 (71.00) 17 100.00 (100.00) 0.5 -29.00 [ -87.91, 29.91 ]
Coulehan 1976 98 95.00 (95.00) 98 100.00 (100.00) 2.2 -5.00 [ -32.31, 22.31 ]
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Study Vitamin C Placebo Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
Ludvigsson 1977a 62 61.00 (41.00) 55 100.00 (67.00) 3.6 -39.00 [ -59.44, -18.56 ]
Ludvigsson 1977b 423 94.00 (85.00) 398 100.00 (114.00) 6.4 -6.00 [ -19.82, 7.82 ]
Miller 1977a 53 93.00 (105.00) 42 100.00 (105.00) 1.0 -7.00 [ -49.51, 35.51 ]
Miller 1977b 42 97.00 (50.00) 40 100.00 (50.00) 3.3 -3.00 [ -24.65, 18.65 ]
Miller 1977c 116 87.00 (73.00) 122 100.00 (73.00) 4.2 -13.00 [ -31.55, 5.55 ]
Ritzel 1961 17 69.00 (51.00) 31 100.00 (51.00) 1.9 -31.00 [ -61.17, -0.83 ]
Wilson 1973a 160 84.50 (131.00) 126 100.00 (134.00) 1.8 -15.50 [ -46.48, 15.48 ]
Wilson 1973b 205 108.00 (150.00) 187 100.00 (132.00) 2.1 8.00 [ -19.92, 35.92 ]
Subtotal (95% CI) 1249 1185 29.8 -13.62 [ -21.63, -5.62 ]
Test for heterogeneity chi-square=12.90 df=11 p=0.30 I² =14.7%
Test for overall effect z=3.34 p=0.0008
Total (95% CI) 5492 4184 100.0 -9.73 [ -14.07, -5.39 ]
Test for heterogeneity chi-square=36.73 df=29 p=0.15 I² =21.0%
Test for overall effect z=4.40 p=0.00001
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Review: Vitamin C for preventing and treating the common cold
Comparison: 03 Severity of colds developing on vitamin C prophylaxis
Outcome: 01 Indicators of severity of episodes experienced while on prophylaxis
Study Vitamin C Placebo Standardised Mean Difference (Random) Weight Standardised Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Mean days indoors or off work or school per episode
Anderson 1972 561 1.04 (1.75) 609 1.32 (2.00) 13.2 -0.15 [ -0.26, -0.03 ]
Anderson 1974a 1823 1.14 (1.71) 437 1.15 (1.52) 13.7 -0.01 [ -0.11, 0.10 ]
Ludvigsson 1977a 62 0.95 (1.12) 55 1.90 (2.42) 4.2 -0.51 [ -0.88, -0.14 ]
Ludvigsson 1977b 423 1.47 (1.27) 398 1.81 (1.79) 12.0 -0.22 [ -0.36, -0.08 ]
Sabiston 1974 6 0.80 (0.80) 14 2.40 (2.10) 0.7 -0.84 [ -1.83, 0.16 ]
Wilson 1973a 160 4.52 (6.32) 126 5.94 (6.28) 7.7 -0.22 [ -0.46, 0.01 ]
Wilson 1973b 205 4.20 (4.44) 187 3.84 (4.51) 9.1 0.08 [ -0.12, 0.28 ]
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Study Vitamin C Placebo Standardised Mean Difference (Random) Weight Standardised Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
Subtotal (95% CI) 3240 1826 60.6 -0.14 [ -0.27, -0.02 ]
Test for heterogeneity chi-square=17.73 df=6 p=0.007 I² =66.2%
Test for overall effect z=2.32 p=0.02
02 Mean symptom severity score per episode
Carr 1981a 94 23.60 (33.57) 70 22.20 (33.57) 5.4 0.04 [ -0.27, 0.35 ]
Carr 1981b 57 21.90 (33.57) 71 33.60 (33.57) 4.5 -0.35 [ -0.70, 0.00 ]
Himmelstein 1998a 15 42.60 (28.66) 12 17.80 (25.98) 1.1 0.87 [ 0.07, 1.67 ]
Himmelstein 1998b 14 16.10 (14.59) 12 37.40 (52.65) 1.1 -0.55 [ -1.34, 0.23 ]
Miller 1977a 53 22.50 (45.50) 42 27.30 (45.50) 3.7 -0.10 [ -0.51, 0.30 ]
Miller 1977b 42 48.60 (22.60) 40 46.20 (22.60) 3.3 0.11 [ -0.33, 0.54 ]
Miller 1977c 116 14.60 (20.00) 122 19.00 (20.00) 7.0 -0.22 [ -0.47, 0.04 ]
Pitt 1979 600 1.87 (0.76) 619 1.97 (0.76) 13.3 -0.13 [ -0.24, -0.02 ]
Subtotal (95% CI) 991 988 39.4 -0.11 [ -0.25, 0.04 ]
Test for heterogeneity chi-square=11.40 df=7 p=0.12 I² =38.6%
Test for overall effect z=1.41 p=0.2
Total (95% CI) 4231 2814 100.0 -0.13 [ -0.21, -0.04 ]
Test for heterogeneity chi-square=29.18 df=14 p=0.010 I² =52.0%
Test for overall effect z=2.86 p=0.004
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Review: Vitamin C for preventing and treating the common cold
Comparison: 04 Duration of colds treated with vitamin C
Outcome: 01 Mean symptom days per episode standardised against control group
Study Vitamin C Placebo Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
Anderson 1974e 900 85.00 (91.00) 437 100.00 (99.00) 20.6 -15.00 [ -26.02, -3.98 ]
Anderson 1975a 419 97.00 (96.00) 213 100.00 (84.00) 15.5 -3.00 [ -17.55, 11.55 ]
Audera 2001a 142 119.00 (79.00) 42 100.00 (76.00) 6.7 19.00 [ -7.40, 45.40 ]
Cowan 1950 77 110.00 (100.00) 76 100.00 (100.00) 4.9 10.00 [ -21.69, 41.69 ]
Elwood 1977 145 99.00 (75.00) 119 100.00 (51.00) 14.7 -1.00 [ -16.26, 14.26 ]
Karlowski 1975c 56 90.00 (41.00) 65 100.00 (52.00) 13.3 -10.00 [ -26.59, 6.59 ]
Tyrrell 1977 274 103.00 (57.00) 329 100.00 (54.00) 24.3 3.00 [ -5.92, 11.92 ]
Total (95% CI) 2013 1281 100.0 -2.54 [ -10.09, 5.02 ]
Test for heterogeneity chi-square=10.35 df=6 p=0.11 I² =42.0%
Test for overall effect z=0.66 p=0.5
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Review: Vitamin C for preventing and treating the common cold
Comparison: 05 Severity of colds treated with vitamin C
Outcome: 01 Indicators of severity of episodes for which vit C was used as therapy
Study Vitamin C Placebo Standardised Mean Difference (Random) Weight Standardised Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Mean days indoors or off work or school
Anderson 1974e 900 1.07 (1.54) 437 1.17 (1.52) 42.6 -0.07 [ -0.18, 0.05 ]
Anderson 1975a 416 0.86 (1.10) 213 1.10 (1.46) 24.7 -0.19 [ -0.36, -0.03 ]
Tyrrell 1977 274 0.33 (0.83) 329 0.34 (1.21) 26.0 -0.01 [ -0.17, 0.15 ]
Subtotal (95% CI) 1590 979 93.3 -0.08 [ -0.18, 0.01 ]
Test for heterogeneity chi-square=2.64 df=2 p=0.27 I² =24.2%
Test for overall effect z=1.73 p=0.08
02 Mean symptom severity score per episode
Audera 2001a 142 32.78 (37.43) 42 29.00 (30.67) 6.7 0.10 [ -0.24, 0.45 ]
Subtotal (95% CI) 142 42 6.7 0.10 [ -0.24, 0.45 ]
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Study Vitamin C Placebo Standardised Mean Difference (Random) Weight Standardised Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
Test for heterogeneity: not applicable
Test for overall effect z=0.59 p=0.6
Total (95% CI) 1732 1021 100.0 -0.07 [ -0.16, 0.02 ]
Test for heterogeneity chi-square=3.71 df=3 p=0.29 I² =19.1%
Test for overall effect z=1.52 p=0.1
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